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ABSTRACT

COORDINATE REGULATION OF THE WNT AND HIPPO PATHWAYS BY THE NOVEL
RAS EFFECTOR NORE1A
Marvin “Lee” Schmidt, Jr.
August 3, 2015

Ras is the most frequently activated oncogene found in human cancer, but its
mechanisms of action remain only partially understood. Ras activates multiple signaling
pathways in order to promote transformation, but can also exhibit a potent ability to
induce growth arrest and death. NORE1A (RASSF5) is a direct Ras effector that acts as
a tumor suppressor promoting senescence and apoptosis. Its expression is frequently
lost in human tumors and its mechanism of action remains unclear. Here I show that
NORE1A forms a direct, Ras regulated, complex with β-TrCP, the substrate recognition
component of the SCF-β-TrCP ubiquitin ligase complex. NORE1A also binds GSK-3β
resulting in enhanced kinase activity, which is required to phosphorylate SCF-β-TrCP
substrates before their recognition by the ubiquitin ligase complex. Thus, by acting as a
scaffold between β-TrCP and GSK-3β, NORE1A allows for Ras to both qualitatively and
quantitatively enhance the proteosomal degradation of SCF-β-TrCP targets, such as βcatenin and TAZ. However, this control is substrate specific, as IκB, another substrate
of SCF-β-TrCP, is not sensitive to NORE1A promoted degradation. Thus, I identify a
vi	
  
	
  
	
  

completely novel signaling mechanism for Ras that allows the coordinate regulation of
the Wnt/β-catenin and Hippo pathways, and potentially multiple other SCF-β-TrCP
targets. The mechanism is frequently impaired in tumors by loss of NORE1A expression
and provides an explanation for the observation that β-TrCP can act as a tumor
suppressor or an oncogene in different cell systems.
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CHAPTER I

BACKGROUND AND INTRODUCTION

1.1 - Overview

Members of the Ras family of small GTP-ase proteins control multiple signaling
pathways responsible for growth, migration, adhesion, cytoskeletal integrity, survival,
and differentiation and come in three closely related isoforms, H-Ras, K-Ras, and N-Ras
[1, 2].

Mutations at codons 12, 13, and 61 render all three Ras isoforms into a

constitutively active state [1]. These Ras mutations have been shown to induce tumors
in experimental systems and can be found in approximately 30% of human cancers [3,
4]. Constitutively activated Ras can stimulate multiple mitogenic signaling pathways,
including the Raf/MAPK, Ral, and PI3K pathways, resulting in oncogenic transformation
[5]. While Ras does indeed activate transformative pathways, it can also activate growth
suppressive pathways promoting apoptosis and Oncogene Induced Senescence (OIS)
[6-8]. However, the mechanisms by which Ras can promote apoptosis or OIS and how
these mechanisms are subverted to facilitate tumor development remain poorly
understood. Current research has shown that Ras induced cell death appears to be
mediated by members of the RASSF family of tumor suppressors, which bind activated
Ras and serve as death effectors [9].

RASSF5, more commonly referred to as

NORE1A, was the first member of the RASSF family to be characterized and has been
implicated in tumor suppressor signaling through the Hippo and p53 pathways [10, 11].
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NORE1A is expressed in most normal tissues, but its expression is lost in many tumors
due to epigenetic inactivation or calpain-mediated proteolysis [10, 12]. In tumors where
NORE1A expression was lost, restoration of NORE1A expression diminished the tumor
phenotype [13].

Moreover, transient expression of NORE1A results in enhanced

apoptosis and senescence [13, 14]. NORE1A is considered to be a bona fide tumor
suppressor, as a hereditary genetic defect in NORE1A predisposes the human carriers
to kidney cancer [15]; however, the biological functions of the Ras/NORE1A interaction
remain mostly uncharacterized.
Research and data detailed in this thesis describes the discovery of a novel
signaling mechanism in which Ras/NORE1A suppresses excessive growth signaling and
promotes cellular senescence by regulating two growth and survival signaling cascade
endpoints via poly-ubiquitination and degradation in the 26S proteasome. Here I will
show that NORE1A can bind the E3 ubiquitin ligase, β -TrCP.

This interaction is

regulated by Ras and powerfully enhances the degradation of the terminal executor of
Wnt signaling, β-catenin. Furthermore, I show that NORE1A can also bind GSK-3β and
enhance its phosphorylation of β -catenin.

Considering that substrates, especially β -

catenin, must be phosphorylated by GSK-3β before recognition and ubiquitination by βTrCP, this observation provides a potential explanation on why NORE1A can efficiently
regulate β -catenin protein stability.

After characterizing NORE1A’s role in Wnt

regulation, I investigated other signaling pathways regulated by both GSK-3β and β TrCP that are implicated in cancer. Regulation of the Hippo and Wnt pathways are
known to be linked [16, 17], so I decided to also investigate the Hippo signaling pathway,
specifically focusing on the functional elements of the signaling cascade, YAP and TAZ.
Initial experiments found that NORE1A suppressed TAZ mediated gene transcription,
while having little effect on YAP transcriptional activity.

TAZ has a GSK-3β

phosphodegron, while its counterpart, YAP, does not [18]. This observation suggested a
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possible mechanism allowing for the differential regulation TAZ over YAP exists. My
experimental work goes on to show that NORE1A indeed specifically regulates TAZ
protein levels independently of canonical Hippo signaling by enhancing GSK-3β
phosphorylation and β -TrCP mediated ubiquitination of TAZ. I also present evidence
that NORE1A is a scaffolding element that is integral in stabilizing GSK-3β and β-TrCP
in a protein complex, providing a mechanistic explanation on how NORE1A enhances
both phosphorylation and ubiquitination of substrates. Finally, I show that the loss of
NORE1A removes a key protection element against excessive growth stimulation and
resulting in a marked increase in steady state levels of β -catenin and TAZ. Thus, I
identify a novel function for NORE1A operating as a Ras regulated scaffold for kinases
and the β -TrCP ubiquitin ligase complex, resulting in enhanced activity towards key
oncogenic targets and suppressing excessive growth and survival stimuli.

1.2 - The Discovery of the Ras Oncogene

Ras genes were initially discovered and characterized as viral genes transduced
from the genome of rodents [19]. Interestingly, these genes are shown to drive the
highly oncogenic characteristics of RNA tumor viruses [19]. The study of these viral
genomes, their conserved eukaryotic cellular complements, along with the 21 kDa (p21)
proteins produced by these genes helped define the fundamental properties of cellular
Ras proteins [19].

The first report characterizing mutationally activated and highly

transforming human Ras genes was made in 1982 [20]. When it was then determined
that Ras mutations are found in very high frequency in human cancers, including three of
the “Big Four” most deadly cancers in the United States: Lung, Colon, and Pancreatic
Cancers; research turn its focus onto Ras and its role in human cancer [19].
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K-, H-, and N-Ras are the founding members of a superfamily of Ras-related
small GTPases that now number more than 150 proteins [19]. Characterization of these
proteins helped establish that small GTPases are operate as multi-functional regulators
of numerous essential cellular processes [19].

When considering how complex the

modes of regulation of the Ras superfamily are, it is easy to see how these proteins are
involved in a spectacularly diverse range of biological processes [21]. Although early
Ras research was established from a long history of research focused on retroviruses, it
was the discovery of mutationally activated Ras genes in human cancer that would ignite
an extensive effort in research focused on understanding Ras protein structure,
biochemistry, and biology [19].

Identification of Ras from acutely transforming retroviruses:

The origins of Ras research begins in 1964 when Jennifer Harvey found that a
sample of purified murine leukemia virus, isolated from a rat suffering from leukemia,
induced the formation of sarcomas in newborn rodents [22, 23].

The tumorigenic

properties of these sequences began to be defined in the early to mid 1970’s when Ed
Scolnick and colleagues determined that the Harvey (Ha-MSV) and Kirsten (Ki-MSV)
viral strains were actually recombinant viruses with sequences collected from the rat
genome [23, 24]. These genes were subsequently identified in the human genome and
determined to be key players in human tumor pathogenesis [20]. In 1973, Ed Scolnick
and colleagues predicted that the tumorigenic properties of these sarcoma viruses likely
resulted from the transduction of normal cellular rat sequences into their own genomics
[25]. Unfortunately, at that time of his prediction, the tools necessary to prove this theory
were not available [19].
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In the beginning, the genes we now refer to as Ras were named as variants of
the src oncogene [19]. They were named Ras (RAt Sarcoma) in part because their
ability to induce rat sarcomas. The discovering scientist’s names then became the basis
for distinguishing each of them from the other: Harvey and Kirsten viral Ras genes, or Hras and K-ras, gives rise to the proteins Ha-Ras, or H-Ras, and Ki-Ras or K-Ras [19].
What would then set the field of Ras research on its end was a report by Varmus,
Bishop, Vogt, and colleagues that characterized the viral src oncogene as a normal
chicken gene transduced by the virus into its own genome, thus transforming a normal
gene into a strong oncogenic element [19, 26].
Scolnick and colleagues extensively studied Ras throughout the late 1970’s and
early 1980’s. This work was then published explaining the eukaryotic origin of the viral
H-ras and K-ras genes, demonstrating that these genes encode 21 kDa proteins that
bind GDP and GTP, and described these proteins as being integrated into the plasma
membrane [27-29]. However, these initial discoveries failed to explain key questions
about Ras signaling including the framework in which Ras proteins function, what
proteins affect signals toward Ras, and how Ras proteins pass signals to downstream
targets in the cell [20]. Early experimental work was slow and complicated because Ras
is controlled through several different positive and negative regulators and can act upon
numerous downstream effectors, each with a defined pattern of tissue-specific
expression and distinct set of intracellular functions. In the 1980’s, several different of
assays were used to detect genetic mutations in Ras and were key in discovering the
roles Ras performs in the pathogenesis of human cancers (Figure 1). These studies
determined that mutations in Ras occur in approximately one-third of all human tumors,
with the highest incidences found in cancers of the pancreas (90%), colon (50%), thyroid
(50%), lung (30%) and leukemias (30%) [30]. However, for most tumor types, the role of
mutated Ras is still unclear and will require a more thorough understanding of the
5	
  	
  
	
  

Reprinted by permission from Macmillan Publishers Ltd:
[Nat Rev Mol Cell Biol] (Karnoub, A.E. and R.A. Weinberg,
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol,
2008. 9(7): p. 517-31.) Copyright 2008
Reproduction Lic# 3683170071733

Figure 1.

Key Events in the Field of Ras Research - A timeline detailing key

moments in the discovery and characterization of Ras.

Discoveries in the 1980’s

explained how Ras is activated and operates as a small GTP-ase protein. In the 1990’s,
Ras effectors were beginning to be identified and their effects on the cell characterized.
From the 2000’s and ongoing today, research continues to work to explain how Ras
plays a role in tumorigenesis.
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mechanisms that regulate Ras along with a better understanding of how Ras acts upon
secondary messenger systems [30].

Identification of Ras as an Oncogenic Human Gene

Although the high oncogenic capability of acutely transforming retroviruses was
well known, the realization that human cancers are not inducted by such infections
quelled the fervor for studying them as a basis of human cancer development [19]. The
researchers took a new course, establishing a new field of study based on the discovery
that biologically active eukaryotic DNA could be inserted into mammalian cells by a
process termed “transfection” [31, 32]. The cornerstone study showing the success of
this type of laboratory procedure and demonstrating that transfected DNA could induce
transforming properties was the use of NIH-3T3 mouse fibroblasts as the transfected
cells [33].

While NIH-3T3 cells are immortalized, they retained some of the normal

growth characteristics of normal cells including density dependent growth inhibition, a
high dependence of serum growth factors, failure to grow in soft-agar experiments, or
form tumors when inoculated into immunocompromised mice [19, 33]. When Weinberg
and colleagues published a study in 1979 showing that when the NIH-3T3 cells were
transfected with DNA isolated from chemically transformed rodent fibroblasts, they
underwent morphologic transformation, the field was once again reinvigorated to
determine the role of Ras in human cancer [34]. Soon after, other labs published similar
reports using the same experimental approach described by Weinberg.

In 1981,

Krontiris and Cooper demonstrated that DNA isolated from the human EJ bladder
carcinoma line also had transforming capabilities [35], and Weinberg’s group also
detected transforming activity in carcinoma and leukemia cell lines [19, 36, 37].
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In

response to these findings, researchers were rejuvenated and focused on the goal of
identifying and isolating transforming human oncogenes.
In 1982, the two concurrent fields of Ras study, which were centered on acute
transforming viral genes and transforming human genes, unexpectedly collided. Three
groups concurrently determined that the transforming genes identified in the NIH-3T3
transfection experiments were actually the same Ras genes previously discovered in the
Kirsten and Harvey sarcoma viruses [38-40]. Further study focused specifically on these
sequences of Ras and found that the oncogenic variants contained a very specific set of
conserved point mutations. These activating Ras mutations commonly result in aminoacid replacements at residues 12, 13, and 61 [41]. In 1983, a third member of the
mammalian family of Ras-related genes, N-ras, was successfully captured and cloned
from neuroblastoma and leukemia cell lines [42]. Remarkably similar to the H-ras and Kras variants, N-ras was also found to contain activating point mutations in human tumors
[43].

1.3 - Discovering Point Mutations of Ras in Human Cancers

Studies using the NIH-3T3 transfection assay, and later analyses using DNA
sequencing assays, detected mutationally activated Ras genes in a broad range of
human tumor cell lines as well as in primary patient tumors [19]. The most conspicuous
of these discoveries was the remarkably high frequency of Ras mutations were found in
colon, lung, and pancreatic cases [44-47]. Moreover, in addition to mutations at codon
12, Ras mutations were later identified at codons 13 and 61 [19]. While there are other
mutations found in Ras, these occurrences are very rare. In fact, mutations at codons
12, 13, and 61 comprise 97-99% of all Ras mutations identified in human tumors and
comprise the three “hot spots” of Ras activation [19].
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The Multi-Hit Model of Oncogenic Transformation

It was not long before the hypothesized role of Ras in the initiation of cellular
transformation was questioned. The ability of mutant Ras genes alone to transform NIH3T3 cells into invasive and tumorigenic cells gave an initially simple and very misleading
picture of the genetic basis of cancer [19].

Complicating the issue, another study

showed that freshly isolated rodent embryo cells would not transform when they
expressed a mutant Ras oncogene on its own [48].

Soon after, three different

manuscripts were published noting the ability of H-Ras-12Val to transform primary cells
that immortalized by the expression of another oncogene, such as myc, SV40 large T
antigen, or the adenovirus E1A gene [20, 48, 49]. These discoveries fell in line with the
Knudson hypothesis of a multi-hit model of carcinogenesis and further suggested that
mutated, constitutively active Ras proteins can only transform cells that have previously
undergone an oncogenic insult [50, 51].
The requirement for a cooperative second oncogenic hit was later supported by
cell culture studies of primary human fibroblasts and epithelial cells where hTERTmediated immortalization, inactivation of the p53 and Rb tumor suppressors, and protein
phosphatase 2A inactivation were all found to help drive Ras-dependent transformation
[52, 53]. This requirement for complementary oncogenic genetic alterations is consistent
with the accumulation of genetic mutations in human colon and pancreatic cancers
combined with the observation that cancer incidences increase with age [19].
A particularly perplexing issue centers on the preferential mutational activation of
specific Ras isoforms in different cancers. There are reports showing that certain types
of human cancers are specifically associated with mutations in either K-, H-, or N-Ras.
More specifically, K-Ras mutations were frequently observed in pancreatic and colon
9	
  	
  
	
  

cancers [54], H-Ras mutations were mostly associated with bladder carcinomas [55],
and finally N-Ras mutations were described as being primarily localized to lymphoid
malignancies [56] and melanomas [57]. However, the reasons for the observed tissue
specificity remain unclear.

1.4 - Mutants of the Ras Oncoprotein and the GTPase Cycle

Once the molecular basis of Ras activation was shown to be caused by DNA
mutation resulting a protein structure alteration, research focused on the origins of
cancer at a molecular level [19].

In 1980, Edward Scolnick and colleagues

investigated the biochemical features of the H-Ras protein. They initially described the
binding of Ras proteins to guanine nucleotides, and determine that Ras may function
analogously to the heterotrimeric G proteins [20, 58]. Heterotrimeric G-proteins were
known to possess an intrinsic GTP hydrolysis activity, simply termed “GTP-ase” activity
[59]. In G-proteins, it is the bound guanine moiety that governs its activity. When a Gprotein is bound to a GTP molecule, the protein is typically in the active state. To shuttle
to an off, or inactive, position, the G-protein will hydrolyze the GTP to a GDP.
Reactivation of the protein occurs when the GDP is exchanged for the more abundant
cellular GTP molecules [59].
A few years later, additional biochemical evidence showed that Ras proteins
were indeed GTP-ases (Figure 2).

Several groups demonstrated that mutated Ras

oncoproteins differ functionally from their normal counterparts because their GTP-ase
activity was impaired [60-62]. Soon after these discoveries, another group identified an
oncogenic link between the Gly à Val substitution found at the 12th residue of H-Ras
and GTP hydrolysis [63]. Moreover, mutations of the 61st residue were also found to be
oncogenic due to disruption of the intrinsic GTP-ase activity of the H-Ras protein [64].
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Figure 2.

The Ras GTP/GDP Activation Cycle - Diagram of the Ras GTP/GDP

activation cycle. When Ras is bound to a GDP moiety, the enzyme is inactive. GEFs
(Guanine Exchange Factor) interact with Ras and facilitate the exchange of the bound
di-phosphate to a tri-phosphate co-factor. The Ras protein is active in this state. While
Ras is able to hydrolyze the GTP to a GDP on its own, the process is quite slow.
However, GAPs (GTP-ase Activating Protein) greatly enhance this speed of this
reaction, returning Ras to the inactive state.
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Thus, the dysfunction in GTP hydrolysis leads to an excessive activation of the Ras
protein. However, increasing degrees of GTP-ase inhibition did not always correlate
with increasing levels of oncogenic transformation, suggesting that compromised GTP
hydrolysis is necessary, but not sufficient, for aberrant Ras activation [20, 65].

1.5 - A Closer Look into Ras Activation

In latter half of 1984, published work concentrating on the functional aspects of
the regulation of Ras activation started to appear in the scientific literature.

The

breakthrough study investigating Ras activation observed that an increase in GTPbinding of cellular H-Ras occurred in response to treatment with epidermal growth factor
(EGF) [66]. Multiple groups subsequently showed that activation or inhibition of Ras
proteins by growth factors and cytokines suggested that Ras proteins, in a fashion
similar to G-proteins, function as signal transducers from membrane-associated
receptors [67-70].
Indeed, studies soon showed that Ras cycles similarly to G-proteins. Luckily, Gproteins were much better characterized than Ras, and share important structural and
sequential homologies, which simplified much of the biochemical and structural research
on Ras [71, 72]. A more comprehensive picture of Ras protein structure emerged when
it was crystallized; showing the conformation of the GDP and GTP bound states as well
as structures of the oncogenic mutants of Ras [73-75]. These studies helped explain the
molecular features involved in the intrinsic GTP-ase activity of Ras and how mutations
result in defects in the Ras activation switch.
The three-dimensional structure of Ras consists of six β -sheets and five α helices that are connected by a series of ten loops (Figure 3) [76]. Five of these loops
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Figure 3.

Three Dimensional Structure of the Ras Protein - Model of the 3-

dimensional structure of the Ras protein. This model highlights the importance of the
12th, 13th, and 61st residues typically found mutated in constitutively activated Ras. The
structure consists of six β -sheets and five α -helices that are linked by a series of ten
loops.

Mutations in residues 12 and/or 13 prevent GAPs from de-stabilizing and

hydrolyzing the GTP to a GDP. The GTP-gamma-phosphate is stabilized by residues
16, 21, 35, 60, and 61.

Of these, residue 61 coordinates the nucleophilic attack

necessary for the hydrolysis of GTP to GDP.
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are found on one lobe of the protein and have functional roles in binding GTP and
regulating GTP hydrolysis.

The GTP γ -phosphate is stabilized by interactions with

residues Lys16, Tyr21, Thr35, Gly60, and Gln61 on loops 1,2, and 4 [73]. Of these
residues, Gln61 appears to coordinate the nucleophilic attack that is necessary for the
hydrolysis of GTP to GDP by stabilizing the transition state of this reaction [73].
Accordingly, mutations in Gln61 significantly reduce the intrinsic GTP hydrolysis rate,
locking Ras in a constitutively active state and making it oncogenic.
Structural analysis of Ras in the GDP and GTP states revealed two highly
dynamic regions, termed Switch I and Switch II [73, 74, 76, 77].

Switch I contains

residues 30-40 and Switch II contains residues 60-76. Both regions are required for Ras
to interact with upstream and downstream signaling elements. Binding of GTP shifts the
conformation of Switch I by shifting Thr35 inward [76]. This allows Thr35 to interact with
the GTP-γ-phosphate as well as the required Mg2+ ion cofactor. In much the same way,
the bound GTP also changes the orientation of Switch II through interactions with Gly60
[76]. Functionality of both switches is required for the Ras protein to successfully cycle
between active and inactive states.
While Ras contains intrinsic GTP-ase activity, kinetic assays show that it is slow
and inefficient.

In fact, differences in GTP-ase activity of Ras compared with its

oncogenic mutants are modest and do not correlate with the degree of transformation
found in tumors [78]. Thus, there must be other cellular elements facilitating Ras’s GTP
hydrolysis action. The discovery of GAPs (GTP-ase Activating Proteins) solved this
dilemma. These proteins alter the conformation of Ras to greatly enhance its GTP-ase
activity, shifting Ras back to an “off” conformation (Figure 2). The explanation began
with an investigation of H-Ras in complex with the p120GAP GRD (GAP-Related
Domain) [79]. Binding of the variable loop of GAP α 7 to Switch I of Ras establishes
specificity between GAP and Ras [79]. This interaction is followed by a high affinity
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interaction with the GAP’s FLR motif (Phe-Leu-Arg), which stabilizes the two switch
domains provoking a rapid acceleration of GTP hydrolysis [79].
Conversely, there are proteins that activate Ras by facilitating the exchange of
GDP for GTP molecules.

These proteins are called GEFs (Guanine Nucleotide

Exchange Factors) and they facilitate the exchange of the GDP molecule in favor of a
GTP molecule (Figure 2). Because of this interaction, an α -helical hairpin of the GEF
separates the Switch I and Switch II domains of Ras, resulting in side-chain
rearrangements centered on Ala59, which inserts itself into the Mg2+ binding cleft [80].
Additional structural shifts found in the phosphate-binding loop cause a massive
enhancement of GDP ejection rates and preferential replacement with a GTP molecule
in the nucleotide binding site [80].

1.6 - Post-translational Modifications of Ras

A pioneering study centered on viral form of H-Ras showed that the protein
localized strongly to the cell membrane [81].

Soon afterwards, another report

demonstrated that the viral H-Ras protein localized to the cell membrane in response to
lipid modifications on the protein’s C-terminus [82].

In 1984, a study described a

correlation between lipid modifications and Ras function and showed that viral H-Ras
proteins had to undergo a lipid modification and integrate into cellular membrane in order
to drive cellular transformation [83]. This hypothesis also held true for the eukaryotic HRas protein, and the investigation concluded that C-terminal processing and membrane
recruitment of Ras is a prerequisite to its subsequent biological activation [84].
The biochemical reactions that lipidate Ras took several years to fully identify
and required a wide array of biological and biochemical experimental systems. Even
though there is a divergence in the C-terminus among the Ras family members, they
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each contain a conserved CAAX sequence (Figure 4). A farnesyl pyrophosphate moiety
is covalently attached to the cysteine residue of a cytosolic Ras protein by a
farnesyltransferase (FTase) [85-87].

The farnesylation is followed by proteolytic

cleavage of the last three amino acids by the Ras-converting enzyme-1 (RCE1), and
finally isoprenylcycteine carboxyl methyltransferase 1 (ICMT1) methylates the last Cys
residue [88]. At this point, a palmitoyltransferase (PTase) transfers a palmitoyl moiety to
the Cys residues slightly upstream of the C-terminus, and the insertion of Ras into the
membrane is stabilized [88].
While C-terminal processing of the CAAX sequence appeared to be essential for
the association of Ras with the cellular membrane, studies of alternate splice variants of
Ras identified a second signaling domain that allows for full membrane recruitment and
full Ras function [88]. K-Ras-4B contains a string of positively charged Lys residues
upstream of the C-terminus. This structural feature can be sufficient to attach the protein
to the membrane. However, the prenylated H-Ras, N-Ras, and K-Ras-4A each require a
further palmitoylation step where a palmitoyl moiety is attached to the C-terminal Cys
residue before anchoring into the membrane is fully stabilized. Enzymes that catalyze
these modifications later become attractive targets for the development of “Anti-Ras”
drug therapies [20].

1.7 - Ras Activates a Wide Range of Effectors

Even though Ras was heavily studied during the 1980’s, at that time Ras’s role in
cellular signaling remained largely unknown. It changed with a key observation from a
study using a microinjection of Ras proteins into rat-embryonic fibroblasts that resulted in
a remarkably fast activation of phospholipase A, an enzyme that hydrolyzes
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Reprinted by permission from Macmillan Publishers Ltd: [Nat Rev Mol Cel Biol]
(Hancock, J. F. (2003). "Ras proteins: different signals from different locations." Nat Rev
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Figure 4. Ras Farnesylation - All Ras family members contain a CAAX sequence on
the C-terminus. A farnesyl pyrophosphate moiety is covalently attached to a cytosolic
Ras protein by a farnesyltransferase (FTase).

This is followed by the proteolytic

cleavage of the last three amino acids of Ras. Finally, the last Cys residue is methylated
and a palmitoyltransferase (PTase) transfers a palmitoyl moiety onto the Cys residues
slightly upstream of the C-terminus , which facilitates and stabilizes Ras’s insertion into
the membrane.
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phospholipids into fatty acids and is implicated in the production the secondary
messenger, arachidonic acid [89].

Subsequently, additional evidence supported the

hypothesis that excessive Ras activation leads to oncogenic transformation [90-92]. At
the time, it was determined whether these cellular responses were direct downstream
reactions to Ras signaling, or pleiotropic effects from over-expression of Ras [90-92]. In
1988, a landmark report was published demonstrating that specific inhibition of a
downstream target of Ras disrupts Ras-induced signaling, suggesting that downstream
cellular effectors are critical for Ras to induce its biological effects [93]. Thus, the term
“Ras Effector” was coined for proteins that Ras acts on to propagate cellular signaling
(Figure 5).
The first bona fide mammalian Ras effector identified was the RAF1 Ser/Thr
kinase [94-97]. In response to mitogenic stimulation, RAF1 was shown to activate the
mitogen-activated protein kinase (MAP Kinase) signal cascade [98].
isoforms

(cRaf,

B-Raf,

and

A-Raf)

are

capable

of

direct

All three Raf

activation

MAPK/extracellular signal-regulated kinases (MEK1/2 kinases) [98].

of

the

These, in turn,

activate the extracellular signal-regulated kinases (ERK1/2), which subsequently
activates the E26-transcription factor proteins (ETS) among other proteins. ETS targets
genes involved in cell proliferation and differentiation. However, over-stimulation of ETS
targets is tumorigenic and results in an oncogenic transformation. This pathway is a
basic template for many signaling cascades that arise at the plasma membrane and
terminate in the nucleus. However, exactly how Raf was recruited to the membrane and
activated by mitogenic receptors remained a mystery until a yeast two-hybrid study
identified Ras and Raf as direct binding partners [96]. Further experiments showed that
Ras-GTP binds preferentially with Raf when compared to Ras-GDP, suggesting that Ras
is the link that transmits signals from mitogenic receptors into the MAPK pathway, and
establishing Raf as a bona fide Ras Effector [96].
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Reprinted by permission from Macmillan Publishers Ltd: [Nat Rev Cancer]
(Malumbres, M. and M. Barbacid, RAS oncogenes: the first 30 years. Nat Rev
Cancer, 2003. 3(6): p. 459-65.) Copyright 2003
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Figure 5. Ras Activated Effectors - Ras activates a wide range of effectors in the cell.
While most of these drive growth and proliferation, there are some that activate
apoptosis and senescence.

The challenge in understanding Ras signaling lies in

determining what is the net result of the Ras signal is and how different cellular contexts
can change the result of Ras stimulation.
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Another

Ras

effector

discovered

by

a

yeast

two-hybrid

screen

is

phosphoinositide 3-kinase (PI3K) [99]. PI3K is involved in the activation of AKT as well
as regulation of the actin cytoskeleton by growth factors such as PDGF and insulin [100102]. Just as Ras requires activation of the MAPK pathway to induce transformation, it
also requires activation of PIK3 to induce transformation of NIH 3T3 cells [99]. These
studies laid the groundwork for future experiments concluding that the anti-apoptotic
effects of Ras stimulation were driven by the pro-survival activities of PIK3 signaling that
propagates through a cascade involving the Ser/Thr kinase AKT and the transcription
factor NF-κB (nuclear factor-κB) [103-105].
Another direct Ras effector, RalGDS (ral guanine nucleotide dissociation
stimulator), was also discovered using a yeast two-hybrid system in 1993 [106]. RalA
and RalB share 46-51% sequence identity with Ras and are members of the Ras
superfamily of small GTP-ases [107].

RalGDS was found to specifically catalyze

nucleotide exchange on both RalA and Ral B, but not on other small GTP-ases [108].
Activation of RalGDS by Ras results in a cooperative activation of Ral. It is believed that
active Ras drives transformation primarily through the binding and activation of RAF,
PI3K, and RalGDS. However, Ras can bind to numerous other downstream effectors
and modulate many cellular activities including endocytosis, actin organization,
cytokinesis, autophagy, gene transcription, and second messenger production [108].
In 2001, phospholipase C-ε (PLCε) was identified as a direct effector of Ras
[109]. PLCε is a key mediator of both Ca2+ signaling and activation of Protein Kinase C
(PKC). Activation of PLCε enables it to cleave phosphatidylinositol 4,5-bisphosphate
into inositol-1,4,5-triphosphate and diacylglycerol (DAG). This cleavage releases Ca2+
and activates PKC. PLCε contains a CDC25 domain, also known as a RasGEF domain.
This suggests that molecule upstream of Ras acting as an exchange factor. In fact,
PLCε has been shown to activate the Ras-MAPK pathway [110].
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About a year passed following the identification of PLCε as a Ras effector before
Channing Der and colleagues published a study that TIAM1 (T-cell lymphoma invasion
and metastasis-1) is also a member of the Ras effector family [111]. TIAM1, a Racspecific GEF, preferentially binds GTP-bound Ras through a conserved Ras-binding
domain leading to activation of Rac in a PI3K-independent manner [111]. Thus, TIAM1
can operate as an effector that directly mediates the Ras activation of Rac. Rac, much
like Ras, is a small GTP-ase signaling protein and has a role in regulating of cell motility,
growth, and invasion.
Ras interaction/interference protein-1 (RIN1), acute lymphoblastic leukemia-1
(ALL-1) fused gene on chromosome 6 (AF-6), and the Ras association domaincontaining family (RASSF) proteins are some of the lesser-known and more poorly
defined Ras effectors. While AF-6 was shown to be involved in mediating transformative
cytoskeletal effects of Ras [112], the other two protein families (RIN1 and RASSF) have
an unexpected ability to block Ras transformation (Figure 6).

RIN1 was originally

described as a Ras effector in 1991 and was the first Ras binding partner with the ability
to block Ras transformation [113, 114]. The affinity of the interaction between Ras and
RIN1 is remarkably high and suggests that RIN1 competes with Raf for Ras binding
[115]. Other models propose that RIN1 triggers endocytosis of Ras-stimulating growth
factor receptors, such as EGFR [116]. Loss of this negative Ras effector has recently
been discovered in breast-tumor cell lines, and restoration of RIN1 expression blocked
anchorage-independent growth in vitro and tumor formation in vivo [117]. Similarly to
RIN1, loss of expression of another family of negative Ras effectors, the RASSF family,
has also been implicated in tumorigenesis.
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Figure 6. Balancing Ras Signaling - Small subset of Ras effectors that show the
importance of negative Ras effectors.

Perhaps one of the roles of negative Ras

effectors is to protect the cell from over-stimulation of Ras by activating pro-apoptotic
genes.

Accordingly, loss of these negative Ras effectors removes key protection

elements against Ras mediated transformation. However, the mechanisms of negative
Ras action have not been fully characterized.
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1.8 - RASSF Family Proteins

Raf and PI3K interact with Ras through their Ras-binding domains, termed RBD
and PI3K-RBD, respectively [118]. However, there is another group of Ras effectors
which share a conserved motif identified as the RalGDS/AF-6 Ras association (RA)
domain [119]. This domain is found in RalGDS, AF6, and more recently in the Rasassociation domain family (RASSF). The RASSF family of tumor suppressors is a group
of non-catalytic proteins encoded by ten genes, each expressing multiple splice variants
[120]. The RASSF family currently consists of RASSF1, RASSF2, RASSF3, RASSF4,
NORE1A (RASSF5), RASSF6, RASSF7, and RASSF8. The founding member was the
Novel Ras Effector 1A (NORE1A), designated RASSF5, which binds directly to Ras in a
GTP-dependent manner [120]. Characterization of RASSF1 proteins followed closely
behind that of NORE1A and they received much attention after both of them were
identified as important physiological tumor suppressors [121].
The role of RASSF1A in tumor suppression was first identified when Loss of
Heterozygosity (LOH) studies centered on lung, breast, and kidney tumors identified
several loci on chromosome 3p that likely contained one or more tumor suppressor
genes [118]. Homozygous deletions in lung and breast tumor cell lines narrowed the
region of 3p21.3 down to a 120kb region in which 8 genes were coded [122, 123]. The
genes CACNA2D2, PL6, 101F6, NPRL2/G21, ZMYND10/BLU, RASSF1/123F2, FUS1,
and HYAL2 were each subjected to in-depth genetic analysis; however, these tests
failed to identity any mutations [118]. While no candidate point mutations were found,
the promoters of the RASSF family were often found to be excessively methylated in
tumors, resulting in their suppressed transcription.
Members of the RASSF family of proteins share a set of highly conserved
domains that are integral in defining how they are activated and how they function in the
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cell. The first 6 members of the RASSF family, RASSF1-RASSF6, all contain a variable
N-terminus but share conserved C-terminal motifs containing a Ras-association (RA)
domain of the RalGDS/AF-6 class and a specialized coiled/coil domain named SARAH
as it mediates interactions with Salvador, RASSF, and Hippo proteins (Figure 7) [118].
The RA domain is responsible for interactions with Ras and other small GTP-ases, while
the SARAH domain mediates protein-protein interactions that are integral in interactions
with the Hippo pathway inducing cell cycle arrest and apoptosis [10]. Even though the
RASSF family all share considerable structural homology, studies show that individual
members of this family perform unique functions in tumor suppression [124]. Although
RASSF1A has been the best studied, another member of the RASSF family, RASSF5 or
NORE1A, appears to be a powerful tumor suppressor, although its full understanding of
its tumor suppressive functions has not been achieved.

1.9 - The Tumor Suppressor NORE1A (RASSF5)

NORE1A (Novel Ras Effector 1 or RASSF5) was the first member of the RASSF
family discovered and is roughly 50% identical to the relatively well-characterized
RASSF1A tumor suppressor [125, 126].

In human tumors, NORE1A expression is

frequently downregulated by promoter hypermethylation or calpain mediated proteolysis
(Figure 8) [11, 12, 126, 127]. Additionally, the NORE1A gene locus has been reported
to undergo a Loss of Heterozygosity (LOH) in some primary tumors [128]. Moreover,
loss of NORE1A via a genetic translocation results in a familial human cancer syndrome
[15]. Studies on NORE1A in vitro show that exogenous expression of NORE1A can
promote apoptosis and cell cycle arrest [10, 11, 129]. In human tumor cell lines deficient
for NORE1A expression, restoration of endogenous levels of NORE1A
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Figure 7. The RASSF Family of Proteins - The RASSF Family of tumor suppressors is
comprised of a group of non-catalytic members encoded by ten genes, each expressing
multiple splice variants. The first 6 members of the RASSF family share a set of highly
conserved domains which are integral in defining how these proteins are activated and
how they function. The first is a Ras-association (RA) domain where Ras associates
with these proteins. The second is a specialized coiled-coil structure called a SARAH
domain (Salvador-RASSF-Hippo).
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Figure 8. Methylation of the CpG Islands Silences Gene Expression - This figure
shows a representative region of genomic DNA in a normal cell and how methylation can
affect transcription.

The region shown contains a repeat-rich hypermethylated

pericentromeric heterochromatin (Left) and an actively transcribed promoter of a tumor
suppressor gene associated with a hypomethylated CpG island (Right). In tumor cells,
repeat-rich heterochromatin becomes hypomethylated and this results in genomic
instability.

Conversely, hypermethylation of CpG islands results in a tumorigenic

phenotype by effectively silencing the gene under the control of this promoter sequence.
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effectively blocks the tumorigenic phenotype [11]. Based on these results, NORE1A
seems to function as a legitimate human tumor suppressor [9, 130, 131].
Like other members of the RASSF family, NORE1A contains a Ras Association
(RA) domain and was identified as a direct Ras binding protein in a yeast two-hybrid
screen (Figure 9) [120]. NORE1A and Ras form an endogenous complex in cells, and
NORE1A binds to the Ras oncoprotein in a GTP-dependent manner with affinities similar
to other known Ras effectors [10, 132]. Therefore, NORE1A is said to be a bona fide
Ras effector.

Mutations in Ras leading to constitutive activation are known to be

transforming; however, activated Ras can also actuate pro-apoptotic and senescent
pathways [7, 14]. NORE1A has been confirmed as a major Ras senescence/apoptosis
effector; however, the mechanisms underlying this activity are poorly understood [10,
14].
Much of the early research on NORE1A was focused on its loss of expression
and established a correlation of this event in cancer. In 2004, the first report detailing a
mechanism of NORE1A mediated tumor suppression was released [129]. Using yeast
two-hybrid screens, NORE1A was shown to bind the MST1/2 kinases [133]. The MST
kinases are the core components of the Hippo pathway which is responsible for the
regulation of cellular apoptosis and senescence (Figure 10) [134].

In the Hippo

pathway, MST kinases drive the signaling cascade by activating the LATS kinases which
in turn phosphorylate the terminal transcriptional co-activators, YAP and TAZ [134]. The
phosphorylation of YAP and TAZ results in their cytoplasmic sequestration and eventual
degradation [134]. Loss of YAP or TAZ transcriptional activity results in the induction of
apoptosis (YAP) and an irreversible cessation of the cell cycle termed senescence (TAZ)
[134].
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Figure 9.

Domains of the NORE1A Protein - The different protein domains of

NORE1A are shown above. The N-Terminus is composed of a Proline Rich domain
followed by a Cysteine Rich Domain (CRD a.k.a. ZnF) and Central region to the protein.
The RA domain is found between residues 268 and 361. This domain binds Ras in a
GTP dependent manner. Finally, the C-Terminus contains the SARAH domain where
NORE1A interacts with other RASSF proteins and elements of the Hippo signaling
pathway.
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Reprinted by permission from Macmillan Publishers Ltd: [Nat Cell Biol] (Zhao,
B., et al. (2011). "The Hippo pathway in organ size control, tissue
regeneration and stem cell self-renewal." Nat Cell Biol 13(8): 877-883.)
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Figure 10.

The Hippo signaling pathway - The Hippo pathway activates

apoptosis/senescence when the terminal transcription co-activators YAP and TAZ are
degraded. On stimulation, the MST1/2 kinases phosphorylate the LATS1/2 kinases.
These mark YAP and TAZ for recognition and ubiquitination by the ubiquitin ligase, β TrCP. However, the potential exists for non-canonical regulation of this pathway by
other kinases and ubiquitin ligases.
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The Avruch group suggested that Ras/NORE1A drives apoptosis by modulating
MST kinase activity. Unfortunately, this study unfortunately failed to conclusively show
that NORE1A was actually enhancing YAP/TAZ phosphorylation [133].

Ironically,

Avruch would later publish work that contradicts this report and shows that NORE1A and
RASSF1A do not activate the MST1/2 kinases; instead he hypothesizes that NORE1A
and RASSF1A control Hippo signaling by altering substrate availability and localization
for MST1/2 activation [135]. Therefore, the role of NORE1A in Hippo signaling remains
controversial at this time.
Complicating the issue further, activation of the MST kinases is generally
considered an apoptotic event; however, NORE1A appears to focus more on mediating
senescence rather than apoptosis [14, 130]. Cellular senescence can be activated by
several mechanisms, including activation of p53, Rb, and TAZ [136-138].

My lab

recently published that NORE1A induces cellular senescence through control of p53
transcriptional activity via HIPK2 [14]. A close analysis of the data suggests that p53
activation is not the only factor that NORE1A modulates to activate senescence.
Perhaps the reason NORE1A is such a potent activator of cellular senescence is
because it can activate multiple senescent pathways.

1.10 - NORE1A and Ras in (Oncogene) Induced Senescence

Normal, untransformed cells are not capable of dividing indefinitely because they
will eventually undergo a process referred to as cellular senescence [139].

This

permanent cell cycle arrest restraining uncontrolled proliferation and tumorigenesis of
cells and is thought be an evolutionally derived protection in higher eukaryotes,
particularly mammals, preventing them from developing cancer [139, 140]. Cells that
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have undergone senescence remain metabolically active; however, they exhibit
characteristic changes ranging from altered morphology to increased senescenceassociated β -galactosidase activity [140]. Senescence was first described in cultured
cells that had exhausted their growth potential after a number of passages in vitro. In
1997, a study was published showing how ectopic expression of oncogenic H-Ras in
normal fibroblasts permanently arrested the cell cycle, suggesting that the senescence
response is a fail-safe mechanism protecting the cells from tumorigenic transformation
[8, 139].
Oncogene Induced Senescence, abbreviated “OIS”, occurs in the G1 phase of
the cell cycle and is associated with a significant increase in the protein levels of p53,
p21, and p16 [8]. Oncogenic activation of Ras activates p53 inducing the senescent
activity of p16 which activates cell-cycle arrest [8]. Previous reports demonstrated that
cells lacking functional Rb overexpress p16 [141]. However, these cells were insensitive
to p16 mediated cell cycle arrest and continued to proliferate [8].

Therefore, Ras-

induced senescence can be bypassed by inactivating the Rb and p53 pathways (Figure
11) [142].
Studies indicate that Ras-induced senescence is not an immediate product of
Ras signaling, but rather a cellular response to aberrant or excessive Ras activity [8].
When primary human and rodent fibroblasts were microinjected with isolated Ras
protein, they proliferated and did not immediately enter senescence until after a lag
period lasting about two days post injection [143-145]. This delayed response is
consistent with a homeostatic mechanism that suppresses proliferation after prolonged
hyper-stimulation by Ras mediated, at least in part, by p53 and p16 [8].
Activating Ras-induced senescence requires a complex web of multiple,
independent signaling mechanisms including ATM, p38, Arf, p16, and FOXO [142].
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Figure 11. Ras (Oncogene) Induced Senescence Mechanisms - Ras stimulation in
normal cells results in an initial wave of proliferation followed by irreversible growth
arrest (senescence). Concurrent with growth arrest, there is accumulation of p53 (via
bypass of MDM2 regulation) and p16 (a CKDI that prohibits G1 to S phase transition and
enhances Rb function) proteins.
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These mechanisms converge on activation of two proteins, p53 and Rb [142]. Yet,
activation of p53 and Rb alone is not sufficient to activate cellular senescence [142]. Rb
and p53 are activated in quiescent cells, but these cells are very different from
senescent cells because their cessation of the cell cycle is reversible. Perhaps this
indicates that senescence requires a threshold level of p53 and Rb activity be reached to
activate the senescent response [142]. Furthermore, in order for p53 and Rb to achieve
this threshold, these proteins potentially require a collaboration of multiple signaling
mechanisms [142].

Thus, signal intensity, tissue type, and tissue microenvironment

might all be factors determining whether the cell activates or suppresses the senescent
response [142].
In normal cells, p53 transcriptional activity increases in response to Ras induced
senescence [8]. The mechanism remained unknown until 2009, when Diego Calvisi and
colleagues linked the senescent Ras effector, NORE1A, to p53 activation [130]. The
study used genomic microarray analysis of HEK-293ecr kidney cells with NORE1A
expression artificially manipulated to endogenous levels and found alterations in gene
expression that closely mimicked those found with other known tumor suppressors [130].
One target, in particular, was the cyclin-dependent kinase (cdk) inhibitor p21CIP1 [130].
Like NORE1A, over-expression of p21CIP1 induces G1 arrest, which made it a potential
target for NORE1A mediated signaling [146].

In fact, the study determined that

NORE1A actually enhances expression of p21CIP1 via the p53 tumor suppressor [130].
While the study by Calvisi and colleagues identified a plausible physiological role
in the regulation of cell cycle arrest by p53, a new study identified NORE1A as a key
component of Ras driven senescence signaling to p53 [14]. The HIPK2 kinase is a
tumor suppressor that performs a wide range of functions within the cell. It has been
shown to regulate apoptosis by directly phosphorylating p53 at the S46 residue,
enhancing p53’s affinity for pro-apoptotic gene promoters [147, 148]. Yet, HIPK2 can
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also recruit acetyltransferases CBP/p300 and PCAF which can acetylate p53 and
modulate its transcriptional activity [148, 149].

Interplay between acetylation and

phosphorylation of p53 likely determines whether p53 activates a more apoptotic or
senescent cellular program.

CBP/p300 acetylates p53 at residue K382 and PCAF

targets K320 [14]. Acetylation at K382 in combination with phosphorylation at S46 shifts
p53 into an apoptotic program; however, without S46 phosphorylation, this K382
acetylation shifts p53 towards a cellular senescence program [150, 151]. Furthermore,
acetylation of K320 has been reported to enhance p53 association with the p21CIP1
promoter, enhancing its expression which results in the activation of cellular senescence
[152]. In the presence of Ras/NORE1A signaling, HIPK2 promotes the pro-senescent
transcriptional program by acetylating p53 at K382 and suppressing the phosphorylation
of p53 at S46 [14]. Moreover, NORE1A induces the pro-senescent acetylation of p53 at
K320 [14]. Thus, cellular levels of NORE1A indeed play an important role in defining
how the cells quantitatively and qualitatively modulate p53 in response to different
stimuli, specifically hyper-active oncogenes [14].

1.11 - Discovering a Novel Role of NORE1A in Tumor Suppression

To gain a better understanding of the mechanism of action of NORE1A, a yeast
two-hybrid screen using full length NORE1A as bait identified several potential binding
partners. One protein in particular, which scored quite high, was the E3 ubiquitin ligase,
β-TrCP. This potential target is intriguing as it is involved in regulating several powerful
oncoproteins including IκB, β-catenin, and MDM2, and its loss of function has been
implicated in several cancers [153-156]. In human tumors, β-TrCP is often found overexpressed; however, it fails to properly regulate key oncogenic pathways including NF-
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κB and Wnt/β-catenin [157]. Adding to this, mutations are rarely, if ever, found in βTrCP [158]. Thus, other factors that affect β-TrCP ubiquitin ligase function including, but
not limited to, the absence of adapter molecules, loss of cooperating kinases, and/or
loss of protein scaffolding molecules are likely absent in cancers.

Therefore, we

hypothesize that NORE1A is a central element involved in β-TrCP mediated protein
ubiquitination and serves as a scaffolding molecule stabilizing collaborating elements to
β-TrCP, including the kinase, GSK-3β.
This dissertation will present data showing that NORE1A does in fact form a
direct, endogenous complex with β -TrCP.

This complex results in the efficient

ubiquitination and degradation of the Wnt signaling endpoint, β-catenin. NORE1A also
forms an endogenous complex with the GSK-3β kinase, which is responsible for the
phosphorylation of substrates, marking them for recognition by the β -TrCP ubiquitin
ligase complex. A mutant of NORE1A that is unable to bind GSK-3β fails to efficiently
regulate β-catenin, suggesting that NORE1A is serving as a scaffold molecule for GSK3β and β-TrCP. Additionally, I will show data demonstrating that NORE1A can “split the
Hippo” by specifically regulating TAZ over its closely related partner, YAP. In Hippo
signaling, activation of the MST kinase cascade results in the ubiquitination and
degradation of the terminal transcriptional co-activators YAP and TAZ. However, newer
research reported that GSK-3β can specifically phosphorylate one of the Hippo pathway
endpoints, TAZ. While NORE1A was initially implicated in Hippo signaling via interaction
with the MST kinases, a mutant of NORE1A that fails to bind MST still effectively
regulates TAZ protein levels in the cell. Thus, the NORE1A mediated regulation of TAZ
can occur outside of canonical Hippo signaling. Furthermore, the mutant of NORE1A
that fails to bind GSK-3β fails to regulate TAZ, suggesting that NORE1A is also working
with GSK-3β and β-TrCP to effectively control TAZ. Suppression of TAZ protein levels is
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known to be a senescent event, so this novel Ras/NORE1A signaling mechanism
provides another way for NORE1A to drive oncogene induced senescence. Finally, data
will show that NORE1A is a scaffold for GSK-3β and β-TrCP, stabilizing them into a
novel protein regulatory complex. Subsequent loss of NORE1A results in an impairment
of this complex, and knockdown of NORE1A results in increased steady state levels of
both β -catenin and TAZ protein levels, resulting in a more aggressive oncogenic
phenotype.
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CHAPTER II

MATERIALS AND METHODS

2.1 - Overview

Isolating and characterizing the growth suppressive functions of important human
tumor suppressor proteins presents several challenges.

These challenges are

compounded by the fact that many signaling pathways have a significant amount of
overlap and cross talk. However, I designed a set of experiments that isolate these
signaling elements and provide key insight into these signaling networks. Work detailed
in this dissertation employs a wide variety of molecular biology and cell/tissue culture
techniques. The goal of these experimental methods is to identify and further and define
the function of the negative Ras effector NORE1A in human tumor suppression. This
section will review these materials and methodology in detail. These discussions will be
grouped in different classes of procedures including molecular biology, cell culture, and
biological assays used in this study.

2.2 – Molecular Biology

Polymerase Chain Reaction – DNA amplification for sub-cloning purposes was
performed using a standard thermocycler by Bio-Rad (Model T100). PCR reactions
were performed using standard PCR master mixes (Invitrogen) with the Platinum Taq
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Polymerase (Invitrogen). Reaction parameters consisted of a 5 minute segment at 95°C
to perform the initial melting of the DNA. Then the reactions were cycled at 95°C for 1
minute, annealing temperatures between 55° and 62°, and 72°C for 1 min/1kb amplified
for 35 cycles. In each case, the annealing temperatures varied slightly with respect to
the specific primers individual predicted annealing temperatures. After the cycling, the
reactions were allowed to undergo the elongation state at 72°C for 7 minutes and then
the reaction was held at 4°C until further processed.

TA/TOPO Cloning – Amplified DNA fragments were subcloned into pCR2.1-TOPO
(Invitrogen) or pGEM-T-EASY (Promega) as each specific protocol dictated. All PCR
reactions were sequenced after TA/TOPO cloning to ensure no errors were introduced
by the Taq polymerase during the PCR amplification step.

Restriction Enzyme Digests – DNA subcloning requires restriction enzyme digests to
allow the alteration of recombinant DNA plasmids. All enzymes used are from New
England Biolabs and were used in reactions consisting of DNA, proper prescribed
buffers (as required), BSA (as required), and enzymes.

Restriction digests were

allowed to incubate for 1 hour at the proper temperature which was most commonly
37°C, yet some enzymes require 25°C.

DNA Ligation – To recombine DNA fragments together, a DNA ligation reaction was
used. In order for two DNA fragments to be joined together, they must be digested with
the same restriction enzymes.

After they are digested and purified, the two DNA

fragments are added to the reaction along with a 10x ligation buffer (NEB) diluted to a
final concentration of 1x. T4 DNA ligase (NEB) was then added to the reaction and the
reaction was allowed to sit overnight at 4°C.
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Agarose Gel Electrophoresis – DNA from PCR and restriction enzyme digests were run
on 1% agarose gels to separate the linearized fragments by size. Agarose gels were
made by adding powdered agarose (SeaKem LE agarose from Lonza Cat#50004) to a
concentration of 1% by weight into a 1x TAE (Tris-Base, Acetic Acid, EDTA) solution
(Diluted from a 10x TAE solution purchased from MediaTech Cat#46-010-CM).
Ethidium Bromide solution (Invitrogen) was then added to the gel solution after melting
and before casting to allow for the visualization of DNA. Gels were then exposed to DC
electric current at roughly 80mA (110V) allowing proper separation of DNA fragments.
In some instances, retrieval of DNA from the agarose gel was required. To achieve this,
the DNA bands were excised and placed into a GenEleute Column (Sigma Cat# 56500)
and processed as the protocol prescribed.

Bacterial Transformation – Chemically competent bacteria were procured from
Invitrogen and I used several types of different competency levels including subcloning
efficiency DH5α, Max Efficiency DH5α, and Chemically and Electrically Competent
TOP10 E. coli (Invitrogen Cat# 18265-017, 18258-012, C5050-03, and K4580-01). For
standard whole plasmid transformation, it is more cost effective to use the subcloning
efficiency DH5α. However, when performing plasmid ligations and TOPO/TA cloning, it
is best to use a higher competency bacterium (Max Efficiency or TOP10 E. coli) as the
mass of complete ligated plasmid is much lower than that of a whole plasmid
transformation. To chemically transform a plasmid into chemically competent bacteria,
the bacteria was mixed with 200ng up to 1µg of plasmid DNA on ice for 30 minutes. The
mixture was then transferred into a 42°C water bath for 30 seconds. After the heat
shock, the bacteria/plasmid mixture was returned to the ice for 2 minutes. 250µL of
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SOC media (Corning Cellgro Cat# 46-003-CR) was then added to the mixture and
placed at 37°C for 1 hour. After the outgrowth stage, the mixture was plated on LB agar
plates containing antibiotics (typically Ampicillin at a final concentration of 100µg/ML or
Kanamycin at a final concentration of 50µg/mL) matching the resistance markers on the
transformed plasmid.

The plates were incubated at 37°C overnight.

The next day

colonies were selected and grown in LB broth media, again supplemented with the
proper antibiotic at the correct final concentrations listed above, and once again
incubated overnight at 37°C in a shaker set at 300 RPM.

After the colonies were

expanded and grown in the LB media, the cultures were processed and the plasmids
were extracted and purified from the bacteria as described below.

Plasmid Purification (Preparation) – DNA plasmids were extracted and purified from E.
coli cultures using kits from Qiagen (Mini-Scale Kit Cat# 27106 and Midi-Scale Kit Cat#
69506 and Midi-Scale Plasmid Kit by Sigma Aldrich Cat# NA0200-1KT). Mini scale
plasmid preparations started with a 5mL culture inoculated from a single bacterial
colony. This inoculation was grown overnight in LB media at 37°C in proper antibiotics
per the plasmids resistance marker. The entire culture was then pelleted using a bucket
centrifuge spun at 5000 RPM for 15 minutes. Following centrifugation, the media was
decanted and the entire pellet resuspended in buffer provided by the kit. From there, the
plasmid extraction and purification were carried out according to manufacturer’s
protocol.

For Midi-Scale plasmid extractions and purifications, a single colony was

isolated form an LB agar plate and grown for 8 hours in 5mL of LB media containing
proper antibiotics at 37°C. The entire culture was then added to 50mL of fresh LB media
containing necessary antibiotics and incubated overnight at 37°C. The next day, the
culture was centrifuged at 5000 RPM for 20 minutes. The supernatant was decanted
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and the remaining pellet was then processed according to the specific Midi-Scale kit’s
protocol.

2.3 – Plasmids

pCR2.1-TOPO – This TA cloning system purchased from Invitrogen has a TOPOIsomerase attached to each end of the pCR2.1 DNA plasmid. Isolated PCR fragments
can be inserted into this vector due to the fact that the Taq polymerase leaves an “A”
overhang on polymerized DNA fragments. The vector is designed with “T” overhangs
allowing for base pair recognition and subsequent isomerization with TOPO to seal PCR
fragments into the plasmid. Colonies can be selected with Blue/White x-gal screenings
to aid in the selection of positive transformants.

pGEM-T-Easy – Working similarly to pCR2.1-TOPO, this system employs a T-4 DNA
ligase instead of a bound isomerase. In some instances, this TA vector system was
more helpful as pCR2.1-TOPO has an internal BglII site, which drops a non-specific
1.5kb band when digested with BglII that sometimes interferes with the retrieval of
inserts with BglII cloning sites. pGEM-T-Easy contains no such BglII site, and allows for
easier cloning of elements requiring BglII restriction digests.

pEGFP-C1 – This mammalian expression construct is driven by a CMV promoter and
allows for an N-Terminal GFP (Green Fluorescent Protein) tag to be fused to cDNAs
inserted into the multiple cloning site. We purchased this plasmid from Clonetech.
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pmKate2-C – This plasmid backbone is practically a base for base copy of pEGFP-C1
except this expression construct expresses an RFP (Red Fluorescent Protein) tag fused
with cDNAs inserted into its multiple cloning site. This construct was purchased from
Evrogen.

pCDNA3 – One of the more ubiquitous mammalian expression plasmids used in
research today, this construct was purchased from Invitrogen. It pairs a CMV promoter
upstream on a multiple cloning site. One of its downfalls is that it does not have a
segment that expresses a fused epitope tag.

Thus, the need to create a pCDNA3

construct with fused epitope tags would become useful in future experiments.

pCDNA3-HA – Using annealed polylinkers inserted into the multiple cloning site of
pCDNA3, the construct now was altered to have an in-frame BamHI fused to a 5’-HA
epitope tag which allows for insertion of genes by a BamHI/EcoRI digest. Expression of
inserted genes results in a fused HA tag on the N-terminus of proteins.

pCDNA3-Flag – Similarly to the pCDNA-HA plasmid, the pCDNA-Flag expression
construct was created in much the same way, except the inserted polylinker expresses
the Flag epitope tag. The construct allows for inserts to receive an N-terminal Flag tag
fused to any expressed protein that is in frame with the 5’ BamHI restriction site. Again,
this construct is designed for inserts to be ligated by restriction digests of BamHI/EcoRI.
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NORE1A – Full length human NORE1A cDNA was obtained from Origene (Rockville,
MD). The NORE1A cDNA clone was then PCR amplified with primers “hNore1a5’” with
the sequence 5’ – GCAGATCTATGGCCATGGCGTCCCCGGCCATC – 3’ and
“hNore1a3’” with the sequence 5’ – GCGAATTCTTACCCAGGTTTGCCCTGGGATTC –
3’ to yield a 1273 base pair DNA fragment with 5’-BglII and 3’-EcoRI restriction sites.
The fragment was TOPO cloned into pCR2.1-TOPO for sequencing and subcloning
applications.

Post-analytical confirmation, the pCR2.1-TOPO-NORE1A plasmid was

digested with BglII and EcoRI and ligated into a BamHI/EcoRI digest of a pCDNA3
(Invitrogen) mammalian expression construct containing an in-frame 5’-HA tag as well as
a pCDNA3 construct containing an in-frame 5’-Flag epitope tag.

The BglII/EcoRI

digested NORE1A fragment was also ligated into both GFP (pEGFP-C1) and RFP
(pmKate2-C) digested with BglII and EcoRI.

NORE1A 92-94A Mutant – I developed a triple point mutant of NORE1A mutating the
92nd to 94th amino acids from Arg to Ala.

To achieve this, two separate NORE1A

fragments were created and ligated together disrupting the 92-94th amino acids. The
first fragment, termed “Upper Fragment” was PCR amplified from the full length
NORE1A cDNA with primers “hNore1a5’” and “Nore3’RMut” with sequence 5’ –
CTGAGCTCCAGGCGCTGCGGCCAGTCTCTGCTGCAGACCAGG – 3’. This yielded a
297 base pair DNA fragment was TOPO cloned into pCR2.1-TOPO for sequencing and
subcloning applications.

The “Lower Fragment” was amplified using primers

“Nore5’RMut” with sequence 5’ – CTGGAGCTCCCCGACCCCGCGACGTG – 3’ and
“hNore1a3’” yielding a 982 base pair band. This fragment was also TOPO cloned into
pCR2.1-TOPO for sequencing and subcloning applications. The mutation was made
using primer over-write from the Nore3’RMut primer which made the mutation and
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installed a SacI restriction site. To complete the mutated cDNA, the Upper Fragment
was ligated into pEGFP-C1 using BglII and SacI.

The Lower Fragment was then

inserted into pEGFP-C1-NORE1A-RMut-UpperFragment by restriction digests with SacI
and EcoRI and subsequent T4 DNA ligations.

Combining the Upper and Lower

Fragments allowed for the mutation of the 92-94th amino acids and completion of the
cDNA. The completed NORE1A92-94A mutant was then subcloned from pEGFP-C1hNORE1A92-94A Mutant (BglII/EcoRI) into pCDNA3-HA (BamHI/EcoRI), pCDNA-Flag
(BamHI/EcoRI), and pmKate-2C (BglII/EcoRI).

NORE1AΔSARAH – The SARAH domain of NORE1A lies on the C-terminal end of the
protein. To remove this domain, full length NORE1A was PCR amplified with primers
“hNore1a5’”

and

“hNore1aDeltaSARAH3’”

with

sequence

of

5’

–

GCGAATTCTTATTAATTCTCCTTTAGCACAAAGC – 3’. The resulting DNA fragment
was then TA cloned into pGEM-T-Easy for sequence analysis and subcloning
applications. After sequence analysis showed that the polymerase produced an error
free product, the pGEM-T-Easy-NORE1AΔSARAH was digested with BglII and EcoRI
and ligated into pCDNA-HA (BamHI/EcoRI), pCDNA-Flag (BamHI/EcoRI), pEGFP-C1
(BglII/EcoRI), and pmKate2-C (BglII/EcoRI).

H-Ras12Val – Constitutively activated H-Ras was expressed with two different tags.
pCGN-HA-H-Ras12V was created by cloning the full-length H-Ras12V cDNA as a
BamHI/EcoRI fragment into the pCGN-HA vector [159]. This cDNA fragment was also
sub-cloned into pmKate-2-C using that vector’s BglII/EcoRI sites yielding the pmKate-2C-H-Ras12V expression construct [131].
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shNORE1A – NORE1A shRNA constructs (Cat# RHS4531-EG83593) were obtained
from Open Biosystems (Rockford, IL).

β-catenin – GFP-β-catenin was generated by a PCR amplification of the human βcatenin cDNA (Addgene #16828) with primers “B-Cat5’BamHI” with sequence 5’ –
GCAGGATCCATGGCTACTCAAGCTGATTTG – 3’ and “B-Cat3’SalI” with sequence 5’ –
GCGTCGACCTTACAGGTCAGTATCAAACCAG – 3’ making a 2.7kb PCR fragment.
The PCR fragment was TA cloned into pGEM-T-Easy (Promega) for sequencing and
subcloning applications.

After sequence verification, pGEM-T-Easy-β-catenin was

digested with BamHI and SalI and ligated into pEGFP-C1 using the same restriction
sites.

β-TrCP - β-TrCP human cDNA was obtained from Addgene (#4489). Using primers “BTrCP5’BamHI” with sequence 5’ – GCGGATCCATGGACCCGGCCGAGGCGGT – 3’
and

“B-TrCP3’SalI”

with

sequence

5’

–

GCGTCGACTTATCTGGAGATGTAGGTGTATGTTCG – 3’, the cDNA clone from
addgene was PCR amplified and the product was TA cloned into pGEM-T-Easy for
sequence confirmation and subcloning applications.

After sequence verification, the

pGEM-T-Easy-β-TrCP plasmid was digested with BamHI and SalI and ligated to pEGFPC1 using the same restriction sites.
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β-TrCPΔFBOX – The dominant negative β-TrCP, GFP-β-TrCPΔFBOX, was a generous
gift from Dr. Tianyan Gao, Associate Professor of Molecular & Cellular Biology at the
University of Kentucky, who kindly shared his plasmid with us.

TAZ – We procured the full length, wild-type HA-TAZ mammalian expression plasmid
from Addgene (#32839).

YAP – We purchased a YAP1 expression construct, pEGFP-C3-YAP1, from Addgene
(#17843) and an RFP-YAP2 was a generous gift from Dr. Howard Donninger, Assistant
Professor of Medicine at the University of Louisville.

GSK-3β - We obtained the HA-GSK-3β and an un-repressible HA-GSK-3βS9Amammalian expression constructs from Addgene (#14753 and #49491).

pGL3-BAR-Luc – This luciferase reporter construct containing a β-catenin Activating
Region (BAR) promoting element upstream of a luciferin response element allowed us to
examine β-catenin transcriptional activity in cell systems. This plasmid was a kind gift
from Randall Moon at the University of Washington, WA.

8xGTIIC-Luc – This reporter for TEAD transcriptional activity was obtained from
Addgene (#34615) and was used to examine YAP and TAZ transcriptional activation of
the TEAD transcription factor.
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TK-renilla – The renilla luciferase control plasmid was obtained from Promega (Madison,
WI). This construct was co-transfected with all luciferase reporters to provide a readout
for transfection efficiency in luciferase assays as the Renilla reporter is constitutively
expressed in mammalian cells. Furthermore, while the main reporter plasmid responds
to the luciferase reaction buffer, renilla does not. Instead, the TK-renilla construct reacts
to the “stop and glo” reagent, allowing for the use of a dual reporter system and separate
RLU readouts contained in the same reaction mix.

2.4 – Antibodies

Mouse-Anti-HA – The antibody against the HA epitope tag was purchased from Covance
(Cat# MMS-101P). For detection of proteins in on a Western blot, the antibody was
diluted at 1:5000 in 5%Milk/TBST (TBS-Tween - 50mM Tris-HCl, pH 7.4, 150mM NaCl,
0.1% Tween 20) and the blot was incubated in the antibody solution overnight at 4°C.
The blots were then probed with a Sheep-Mouse-IgG-HRP (Amersham Cat# NA9311ML) secondary antibody diluted at 1:20000 in TBST for one hour at room temperature
and detected by West Pico Enhanced Chemi-Luminescence (Pierce Cat#34080).

Mouse-Anti-GFP – The antibody detecting the GFP-epitope tag was purchased from
Santa Cruz Bio-Technology (Cat# SC-9996). For detection of proteins on a Western blot
containing a GFP epitope tag, the GFP-antibody was diluted at 1:200 in a 5%Milk/TBST
solution.

The blot was incubated in the antibody solution overnight at 4°C.

After

incubation in the primary antibody, the Western blot was exposed to a Mouse-IgG-HRP
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secondary (Amersham) at a dilution of 1:15000 in TBST for 1 hour at room temperature
and detected by West Pico ECL.

Rabbit-Anti-RFP (Kate) – For detection of the Katushka (pmKate-2-C RFP Epitope Tag),
I used the Anti-tRFP antibody from Evrogen (Cat#AB233,234). This rabbit polyclonal
antibody was incubated overnight at 4°C at a dilution of 1:2000 in a 5% BSA/TBST
solution. The blots were then probed with a Goat Anti-Rabbit secondary antibody (KPL)
at a dilution of 1:10000 in TBST for 1 hour at room temperature and detected using West
Pico ECL (Pierce).

Mouse-Anti-Flag – For detection of the Flag epitope tag, I used an Anti-Flag primary
antibody was purchased from Sigma Aldrich (Cat# F1804). This antibody was diluted at
1:1000 in a 5%Milk/TBST solution and incubated on the Western blot overnight at 4°C.
After incubation in the primary antibody, the Western blot was exposed to a Mouse-IgGHRP secondary (Amersham) antibody at a dilution of 1:15000 in TBST for 1 hour at
room temperature and detected by West Pico ECL.

Rabbit-Anti-Human-β-TrCP – Detection of endogenous β-TrCP was performed by an
Anti-β-TrCP primary antibody purchased from Cell Signaling Technology (Cat# 4394).
Western blots were incubated in the Anti-β-TrCP antibody at a dilution of 1:2500 in a 5%
BSA (Sigma Aldrich Cat# A3059-100G)/TBST solution overnight at 4°C. After incubation
in the primary antibody, the blot was then exposed to a Goat Anti-Rabbit-HRP secondary
antibody (KPL Cat# 374-1506) at a dilution of 1:20000 in TBST for 1 hour at room
temperature. The blot was developed using West Pico ECL.
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Rabbit-Anti-Human-β-catenin – Endogenous β-catenin proteins were detected on
Western blots using an Anti-β-catenin antibody from Cell Signaling Technology (Cat#
8814). The antibody was diluted into a 5%BSA/TBST solution at 1:2000 and incubated
on the blot overnight at 4°C. The blot was then exposed to a Goat Anti-Rabbit-HRP
secondary antibody (KPL) at a dilution of 1:20000 in TBST for 1 hour at room
temperature and developed using West Pico ECL.

Rabbit-Anti-Human-phospho-β-catenin (Ser33/37 Thr41) – To detect the fraction of βcatenin that was phosphorylated by GSK-3β, I used an antibody against Phospho-βcatenin on residues Ser33/37 and Thr41 purchased from Cell Signaling Technology
(Cat# 9561).

Western blots were exposed to this antibody diluted at 1:2500 in a

5%BSA/TBST solution overnight at 4°C. The Goat Anti-Rabbit-HRP was subsequently
applied at a dilution of 1:20000 in TBST for 1 hour at room temperature and the blot was
detected using West Pico ECL.

Mouse-Anti-NORE1A – Monoclonal NORE1A antibodies were a gift from A.
Khokhlatchev (University of Virginia, Richmond, VA) and were raised against human
NORE1A amino acid residues 119-416.

This antibody was used for detection of

NORE1A on Western blots and also for immunoprecipitations (IP). For Western blot
detection, the antibody was added to a 5% Milk/TBST solution at a 1:500 dilution and
incubated with the blot overnight at 4°C. The blot was then probed with a mouse-IgGHRP (Amersham) secondary antibody for 1 hour and detected with a West Pico ECL.
For immunoprecipitations, 1mg of whole cell lysate was incubated with 10µL of the
antibody in 1mL final volume of modified RIPA buffer overnight and then
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immunoprecipitated on Mouse conjugated agarose beads.

For full IP protocol, see

section “2.7 - Immunoprecipitations”.

Rabbit-Anti-Human-GSK-3β - Endogenous GSK-3β was detected on a Western blot by
an antibody from Cell Signaling Technology (Cat#9315) diluted 1:2000 in a
5%BSA/TBST solution.

The antibody solution was incubated with the Western blot

overnight at 4°C followed by exposure to a Goat Anti-Rabbit-HRP secondary antibody
diluted at 1:15000 in TBST for 1 hour at room temperature and detected using West Pico
ECL.

Rabbit-Anti-Human-TAZ – When Western blotting for endogenous levels of TAZ protein,
an Anti-TAZ antibody purchased from Cell Signaling Technology (Cat# 4883) was found
to perform well. This antibody was diluted at 1:1500 in a 5%BSA/TBST solution and
incubated with the blot overnight at 4°C. Following the overnight incubation, a Goat AntiRabbit-HRP secondary antibody was added at a dilution of 1:20000 in TBST for 1 hour
at room temperature and the blot was detected using West Pico ECL.

Rat-Anti-Mouse-HRP TrueBlot Secondary Antibody – Rockland’s TrueBlot product line is
an HRP conjugated immunoblotting detection reagent that does not detect heavy and
light chain IgG bands. This technology is very useful when using agarose-conjugated
beads that are bound with mouse or rabbit secondary antibodies and yields a much
cleaner blot.

In some instances, this secondary antibody was used instead of the

standard HRP-mouse secondary antibody listed above.

When the Mouse TrueBlot

(Rockland Cat# 18-8817-33) antibody was used, it diluted at a 1:2000 dilution in a 5%
Milk/TBST solution and incubated on the blot for 2 hours and detected with the West
Pico ECL.
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Mouse-Anti-Rabbit-HRP TrueBlot Secondary Antibody – Used in similar applications to
the Mouse TrueBlot secondary antibody, this Rabbit-HRP (Rockland Cat#18-8816-33)
secondary also does not detect the heavy and light chain IgG from Rabbit secondary
antibody conjugated agarose beads. It is also used at a 1:2000 dilution in 5% Milk/TBST
solution and exposed on the blot for 2 hours and developed with West Pico ECL.

2.5 – Cell Lines

HEK-293 – This cell line composed of human embryonic kidney cells was derived from
an aborted human embryo and acquired from ATCC. These cells transfect very easily
and allow for a nice functional platform for transgenic experimentation.

This line is

cultured in DMEM (explained in the next section) supplemented with 10% FBS (Fetal
Bovine Serum).

HEK-293T – The HEK-293T cells are derived from HEK-293 cells, but they have been
altered to stably express the SV40 Large T Antigen that can bind SV40 enhancers
commonly found in expression vectors to increase protein production. We purchased
these cells from ATCC.

The Large T Antigen also suppresses p53 and Rb tumor

suppressive activity allowing for a more tolerable phenotype to transgenic studies.
These cells are cultured in the same way as the HEK-293 cells.

NCI-H1299 – Also known as H1299, this cell line is a human non-small cell lung
carcinoma derived from a lymph node and we purchased this line from ATCC. Similarly
to other immortalized cells, the H1299 line can divide indefinitely. These cells have a
homozygous partial deletion of the p53 gene, and thus do not express the p53 tumor
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suppressor.

Furthermore, this cell line also contains a point mutant NRAS-Q61K

resulting in a constitutively activated Ras signaling phenotype. These cells are cultured
in RPMI cell growth medium supplemented with 10% FBS.

A549 – These cells are adenocarcinomic human alveolar basal epithelial cells derived
from the removal and culture of cancerous lung tissue and acquired from ATCC. This
line also contains a point mutation in KRAS (G12S) resulting in the constitutively
activation of KRAS signaling.

This line, however, was ideal for studies on cellular

senescence as they are wild-type for p53 and Rb signaling, two elements known to be
necessary for the induction of senescence.

These cells are cultured in DMEM

supplemented with 10% FBS.

HBEC-3KT – These normal Human Bronchial Epithelial Cells were a generous gift from
Dr. Jerry Shay, The Southland Financial Corporation Distinguished Chair in Genetics,
Department of Cell Biology, University of Texas Southwestern Medical Center, and were
used to examine how knockdown of specific members of the RASSF family of tumor
suppressors along with Ras stimulation results in oncogenic cellular transformation [14].
These cells require a special growth medium and I selected Keratinocyote-SFM medium
purchased from Invitrogen.

MCF-10A – This cell line is a non-tumorigenic epithelial cell line derived from human
mammary gland/breast tissue. These cells are immortalized without the use of viral
oncogenes giving them primary cell phenotypes.

I used this cell line extensively to

perform endogenous co-immunoprecipitations of proteins and makes for an excellent
system to examine how loss of tumor suppressors along with Ras stimulation can result
in an oncogenic phenotype in several different biological assays.
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These cells are

responsive to insulin, glucocorticoids, cholera enterotoxin, and epidermal growth factors.
MCF-10A require a specialized growth media and were cultured in a 50%/50% mixture
of DMEM and Ham’s Nutrient Mixture F-12 supplemented with horse serum, insulin, and
EGF.

2.6 – Cell Culture and Transfections

All cell culture was processed inside a laminar flow biological safety cabinet per
protocol from the Department of Environmental Health and Safety, the University of
Louisville, and the Occupational Safety and Health Administration.

All cells were

cultured on T-75 and T-25 cell culture flasks (TPP), 100mm and 60mm cell culture
dishes (Greiner Bio-One), and 6, 12, and 24 well cell culture plates (Greiner Bio-One).
Different cells cultured sometimes require different culture media as previously listed.
The descriptions of the media used is as follows:

DMEM – Dulbecco’s Modified Eagle’s Medium was purchased from Corning Cellgro
(Cat# 10-013-CV) and is composed of 4.5g/L glucose and supplemented with Lglutamine and pyruvate. The DMEM was further supplemented with 10% FBS (Valley
Biomedical) and 1% Pen-Strep Antibiotic (Corning Cellgro Cat# 30-002-CI).

RPMI – RPMI 1640 cell culture medium was purchased from Corning Cellgro (Cat# 10040-CV) with L-glutamine.

This medium was further supplemented with 10% FBS

(Valley Biomedical) and 1% Pen-Strep Antibiotic (Corning Cellgro).

Keratinocyte-SFM – HBEC cells require a special growth media formulation and I
purchased this medium designed for keratinocytes from Invitrogen (Cat# 17005-042).
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This kit contains Keratinocyte-SFM medium (Cat# 10724-011) which was supplemented
with provided supplements 25mg Bovine Pituitary Extract (BPE) (Cat# 13028-014),
2.5µg human recombinant EGF (Cat# 10450-013), and 1% Pen-Strep Antibiotic (Corning
Cellgro).

DMEM/Ham’s-F12 50/50 Mix – This media is a 50%/50% mixture of two different cell
culture growth mediums, DMEM and Ham’s Nutrient Mixture F-12 and was purchased
from Corning Cellgro (Cat# 15-090-CV). This medium was further supplemented with
5% horse serum (Sigma Aldrich Cat# H1270), human insulin (Sigma Aldrich Cat# I92781ML) to a final concentration of 10ug/mL, and recombinant epidermal growth factor
(Invitrogen Cat# PHG0311) to a final concentration of 10ng/mL, and hydrocortisone
(Sigma Aldrich Cat# H6909) to a final concentration of 0.5ug/mL.

PBS – Phosphate Buffered Saline was purchased from Corning Cellgro (Cat# 21-040CV and #46-013-CM) and used to wash cells and other routine cell culture applications
as required.

Trypsin EDTA 0.25% - We purchased this trypsin solution (Corning Cellgro Cat# 25-053CI) to remove adherent cells from culture dishes and flasks. Media was removed by
aspiration from cell culture dishes and washed once with 1xPBS. The PBS was then
aspirated and the trypsin-EDTA solution was then added, covering the bottom of the dish
with a thin layer of solution. The dishes were then placed back into the incubator for 3-5
minutes allowing the trypsin to remove adherent cells. After the cells were removed
from the flask, the trypsin-EDTA was neutralized with supplemented culture medium and
the cells were pelleted by centrifugation (5 minutes at 1500 RPM). The cell pellets were
resuspended in culture medium and plated as the application required.
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RIPA Buffer – For applications where we were not investigating protein/protein
complexes, I lysed cells in a RIPA Buffer (Sigma Aldrich Cat# R0278).

This buffer

contains 150mM NaCl, 1.0% IGEPAL® CA630, 0.5% sodium deoxycholate, 0.1% SDS,
and 50mM Tris pH 8.0. This buffer allows for efficient cell lysis and exceptional protein
stabilization for analysis on a Western blot.

G418 Sulfate – For selection of cells expressing a G418 resistance marker, G418 sulfate
(Corning Cellgro Cat# 30-234-CR) was added to growth media at a final concentration of
500µg/mL.

Puromycin – For selection of cells expressing a puromycin resistance marker,
Puromycin dihyrochloride (Sigma Aldrich Cat# P8833-10MG) was added to cell culture
media at a final concentration of 1µg/mL

MG132 – To inhibit the 26S proteasome, cells can be treated with a chemical named
MG132 (Sigma Aldrich Cat# C2211-5MG). To make a working stock of MG132, stock
powder was dissolved in DMSO to a final concentration of 10mM and used in cell culture
media at a final concentration of 10µM for 8-24 hours. The drug is reversible, so care
must be taken to not let the drug effects fade and time experiments properly.

Cycloheximide – Cycloheximide (CHX) is an antibiotic produced by the S. griseus
species that inhibits protein biosynthesis in eukaryotic cells.

It inactivates the

transferase II enzyme that is involved in peptide chain elongation. It is used in studies to
analyze protein stability.

Stock powder (Sigma Aldrich Cat# P8833-10MG) was

dissolved in 100% EtOH to a final concentration of 20mg/mL. For use in cell culture to
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inhibit transcription, CHX was added to the cell culture medium at a final concentration of
20µg/mL.

Farnesyl Transferase Inhibitor (FTI) – FTI-277 was obtained from CalBiochem (LaJolla,
CA) and was used to chemically inhibit Ras signaling by impeding its ability to bind the
cell membrane. The inhibitor was added to cell culture media at a final concentration
10µM.

Cell Transfections - Cells were transfected using several options available in the
laboratory.

Commonly the HEK-293, HEK-293T, H1299, and MCF-10A cells were

transfected with JetPRIME (Polyplus) transfection reagent. A549 cells were transfected
with Lipofectamine 3000 Transfection Reagent (Invitrogen) as the JetPRIME reagent did
not have sufficient efficiency when transfecting this line. Transfection reagent specifics
and methodology are listed below.

JetPRIME™ - The JetPRIME™ DNA transfection reagent (VWR Cat# 89137-972) is
described by the manufacturer as a novel and versatile cationic polymer-based reagent
designed to ensure high DNA transfection efficiency.

JetPrime™ forms positively

charged complexes with DNA that can penetrate the cell membrane through endocytosis
and release DNA into the cytoplasm of the cell via the “proton sponge mechanism”.
Plasmids mostly reach the nucleus when the nuclear envelope disappears during
mitosis. 1-2µg of specific DNA plasmids were mixed in 100µL (35mm dish) to 200µL
(60mm dish) of the provided JetPrime™ Transfection Buffer. To this mixture, 2µL of
JetPRIME™ was added per 1µg of DNA to be transfected.

The mixture was then

vortexed for 15 seconds and the transfection mixture was allowed to incubate for 10
minutes at room temperature.

The entire mixture was then added to the dish and
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allowed to sit for at least 6 hours. After 6 hours, culture media could be changed if
complications with cytotoxicity arise.

Lipofectamine 3000® - This transfection reagent is a proprietary lipid formulation
purchased from Invitrogen (Cat# LC3000015).

Lipofectamine 3000® is especially

designed for hard to transfect cells, and I found this to be much more successful at
transfecting A549 cells than when I used JetPRIME™. To begin the process, cells were
seeded to be 70-90% confluent prior to addition of transfection reagent. Two tubes each
containing 125µL of Opti-MEM (Invitrogen Cat# 31985062) were prepared.

The

Lipofectamine 3000® was then added to each tube, 3.75µL in the first tube and 7.5µL in
the second. Next, a DNA master mix was prepared by diluting 1-2µg of each DNA
plasmid into 250µL Opti-MEM and adding 2µL of P3000™ per 1µg of DNA.

This

solution was mixed well and then 125µL was added to each previously prepared tube
containing the Lipofectamine 3000® reagent. These mixtures were then allowed to sit
for 5 minutes at room temperature, making a high and low lipid dose of transfection for
each dish. After the incubation, both high and low mixtures were added to the proper
dish and allowed to sit on the cells for 6 hours. After this time, the culture media was
changed and the cells incubated overnight to begin expressing recombinant plasmids.

2.7 – Immunoprecipitation

One of the best ways to detect and examine how proteins interact with each
other is the co-Immunoprecipitation assay.

This assay uses an antibody, typically

conjugated to an agarose bead, to bind and precipitate a specific protein.

The

precipitation is then analyzed for the presence or absence of other proteins that were
bound to the precipitated protein.

This assay presents several challenges from
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insufficient cell lysis, inadequate purification of proteins, non-specific precipitation, and
high background detection. Caution must be taken at every step to minimize these
issues.

Immunoprecipitation of Over-Expressed Proteins – Transfected cells were lysed 24 to 48
hours post-transfection in a modified RIPA buffer. Modified RIPA buffer is composed of
50mM Tris-HCl pH7.4, 200mM NaCl, and 1% NP-40. Cells were plated in 60mm dishes
for over-expression studies and 350µL of modified RIPA buffer was added to each dish
to begin the lysis process. Cells were then scraped and collected in microfuge tubes
and placed on a rotator for 3 hours at 4°C. After rotation, each sample was then slowly
passed through a 25 gauge syringe needle 4 times and then centrifuged at 10,000 RPM
for 5 minutes at 4°C. The supernatant was then removed from the insoluble pellet and
quantified using a Bio-Rad protein quantification assay (Bio-Rad Cat# 500-0006). To a
new microfuge tube, 1mg of total protein was added and modified RIPA buffer was
added to reach a final volume of 1mL. Agarose beads were then added matching the
specific epitope tag of one of the over-expressed proteins. For HA precipitations, I used
5µL of HA-conjugated agarose beads prepared as the manufacturer’s protocol
prescribed (Sigma Aldrich Cat# A2095-5ML). To precipitate the Flag epitope tag, 5µL of
Anti-Flag M2 Affinity Gel (Sigma Aldrich Cat# A2220-5ML) was prepared according to
the manufacturer’s protocol and added to the cleared cell lysate.

And finally, for

precipitation of the GFP epitope tag, GFP-Trap® (Allele Biotech Cat# ABP-NABGFPA100) was used according to manufacturer’s protocol. In each case, the cleared
cell lysate was rotated overnight at 4°C with the proper agarose conjugate. The next
day, the bead/lysate mixture was centrifuged for 3 minutes at 3000 RPM at 4°C to pellet
the agarose. The supernatant was then removed by aspiration and the beads were
washed with 1mL of modified RIPA buffer, repeating this process three times. After the
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final wash, the beads were resuspended in 10µL of standard RIPA buffer and 5µL of 4x
LDS (Lithium Dodecyl Sulfate) sample running buffer purchased from Invitrogen (Cat#
NP0007). The IP samples and lysate controls were then run on an SDS-PAGE gel and
analyzed by Western blot.

Immunoprecipitation of Endogenous Proteins – Conversely to over-expressed proteins,
endogenous proteins do not contain epitope tags and must be immunoprecipitated
slightly differently than over-expressed proteins. Cells were lysed in a modified RIPA
buffer and again 1mg of total cell lysate was set-aside in a final volume of 1mL. Then a
primary antibody against the target protein was added and rotated overnight in the
protein lysate at 4°C. The next day, an agarose conjugated secondary, typically mouse
or rabbit (Rockland Cat# 00-8800-25 and 00-8811-25), antibody was added and rotated
for 2 hours at 4°C to capture the primary antibody/target protein complex.

Then

mirroring the previously described method, the agarose beads were collected by
centrifugation at 3000 RPM for 3 minutes at 4°C. The beads were washed 3 times with
1mL of modified RIPA buffer. Following the wash steps, the beads were resuspended in
10µL of standard RIPA buffer and 5µL 4xLDS sample running buffer. The IP along with
controls were analyzed by Western blot.

2.8 – Western Blotting

Sample Preparation – Cell lysates and protein samples were combined with a 4x LDS
Sample Buffer (Invitrogen Cat# NP0008) containing 10% β-Mercaptoethanol (Sigma
Aldrich Cat# M6250-100ML) to a final concentration of 1x. The protein sample/LDS
mixture was then incubated at 95°C for 10 minutes to allow for the denaturation of the
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protein sample, allowing for a more consistent separation of size in the polyacrylamide
gel.

SDS-PAGE – Prepared protein samples were then loaded on a pre-cast 4-12% TrisGlycine Polyacrylamide Gel (Invitrogen Cat# EC60352BOX) which is immersed in 1x
Tris-Glycine SDS Running Buffer (Invitrogen Cat# LC2675-5). The gel was run at 150V
until the loading dye reached the bottom of the gel. The gel was then removed from the
running buffer and prepared for transfer onto a nitrocellulose membrane.

Nitrocellulose Transfer – The protein gel was transferred onto a 0.2µm pore size
nitrocellulose membrane by electrophoresis in 1x Tris-Glycine Transfer Buffer (Invitrogen
Cat# LC3675) supplemented with 20% methanol for 3 hours at 20V DC power.

Western Blot Detection – After transfer, the nitrocellulose filter was blocked in a 5%
Milk/TBST solution for 30 minutes and then the blot was incubated in primary and
secondary antibodies as previously explained earlier in this chapter. After primary and
secondary antibody probes were complete, the blots were detected using an ECL
solution and exposed to chemiluminescent detection film.

2.9 – Biological Assays

Luciferase Assay – Dual luciferase assays were performed using reagents from
Promega’s Dual Lucifease Assay Kit (Cat# E1960) per the manufacturer’s protocol.
Cells were transfected for 24-72 hours depending on the reporter construct used before
being lysed in 200µL of the provided passive lysis buffer.

20µL of sample was

processed with 70µL of each buffer in sequence to give a primary RLU (Relative Light
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Units) reading following by a secondary standardization RLU reading on a Lumat 9507
machine from Berthold Technologies. Data was analyzed with the RLU1 value divided
by the RLU2 value resulting in a numerical figure representing relative promoter
activation.

Senescence Assay – One of the hallmarks of cells that have undergone senescence is
an increase in β-glactosidase activitiy. The Senescence Detection Kit from BioVision
(Cat# K320-250) is designed to histochemically detect β-gal activity in cultured cells and
tissue sections. A549 cells were plated onto 12-well culture dishes at 40,000 cells per
well initial seeding. The next day, the cells were transfected with expression constructs
to analyze their effects on the induction of cellular senescence.

72 hours post-

transfection, the cells were processed with the Senescence Detection Kit per the
manufacturer’s protocol. Five random fields were counted in each well and the number
of blue cells counted was divided by the total number of cell counted in the entire field.
The result yeilds a value that shows percentage of cells in senescence.
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CHAPTER III

RAS REGULATES SCF-β-TrCP ACTIVITY AND SPECIFICITY VIA NORE1A

3.1 - Introduction

Mutations in the Ras oncogene can be detected in roughly one third of human
cancers [23]. When activated, the Ras oncoprotein drives growth and transformation by
binding and activating multiple effectors that stimulate multiple signaling pathways.
Three of the best characterized cascades are the Raf, PI-3Kinase, and RalGDS effector
pathways [160].

However, Ras can also impact other signaling pathways important to

proliferation and development, such as the Wnt/β-catenin signaling pathway [161]. The
interaction of the Ras and the Wnt/β-catenin signaling pathways is quite complex and
appears to occur at multiple levels [162-164]. An interesting dichotomy exists, as Ras
has been reported to exhibit both positive and negative effects on the pathway [162164]. Moreover, although synergistic activation of transformation by Ras and Wnt/βcatenin has been reported, other reports have identified an antagonistic role in
transformation [163, 164]. How Ras impacts the Wnt/β-catenin pathway is still not fully
understood. Nor is the balance of cellular factors that dictate whether a net positive or
negative effect is observed for Ras on Wnt/β-catenin pathway signaling.
Similarly to many other oncogenic signaling pathways, members of the Wnt
signaling pathway can be subdivided in positively and negatively acting components
[165]. More often than not, the negative acting components are found mutated to a loss
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of function status in cancer, while the positively active components are found
constitutively activated [165].

Improper regulation of the Wnt signaling pathway

transcriptional co-activator, β-catenin, is an oncogenic force in human cancers.
Beginning with the first observations that β-catenin overexpression could lead to
malignant transformation and continuing today, the Wnt/β-catenin pathway continues to
evolve as a central mechanism in tumorigenesis [165].
In the canonical Wnt/β-catenin pathway, β -catenin is the terminal executor,
serving as both a nuclear transcriptional co-regulator and key component of adherens
junctions [166].

In the absence of Wnt ligand signaling, a multi-protein complex

consisting of APC, Axin, and GSK-3β, phosphorylates β-catenin. This phosphorylation
is necessary for the binding of β-TrCP, the substrate recognition component of the SCFβ-TrCP

ubiquitin ligase complex. SCF-β-TrCP mediated ubiquitination of β-catenin results in

its rapid degradation by the 26S proteasome [167]. In response Wnt ligand activation of
the Frizzled receptor, the GSK-3β phosphorylation complex is destabilized by
Disheveled family proteins allowing for unphosphorylated β -catenin levels to quickly
increase in the cytoplasm and translocate to the nucleus. The nuclear pool of β-catenin
functions as a cofactor for transcription factors of the TCF/LEF family, modulating genes
involved in growth and survival [168].
Beta-transducin repeats-containing proteins (β-TrCP) serve as the E3 substrate
recognition subunits for the SCFβ-TrCP ubiquitin ligase complexes [157]. The ubiquitin
proteasome system controls the degradation of the majority of regulatory eukaryotic
signaling proteins, including proteins that perform central functions in tumorigenesis, like
β-catenin, IκB, YAP, and TAZ [157, 169]. E3 ubiquitin ligases determine the timing and
specificity of ubiquitination for substrates and typically target proteins with a very specific
set of post-translational modifications including phosphorylation or hydroxylation [157].
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Beta-TrCP is expressed at relatively low levels in the cell and its function can be easily
disrupted by the expression of a dominant negative construct, which lacks an F-Box
domain making it unable to bind the other members of the SCF ubiquitin complex [170,
171]. Furthermore, the activity of β-TrCP can be controlled by several different cellular
mechanisms that can alter its localization, relative abundance, and levels of
phosphorylated substrates [157]. Interestingly, levels of β -TrCP are often elevated in
tumor cells, yet in these cells β-TrCP fails to properly regulate its usual oncogenic
substrates, including β-catenin [157, 172]. This suggests that presence or absence of
other scaffolding elements can alter its ubiquitin ligase activity and/or specificity.
While cells constitutively synthesize β -catenin to remain ready to respond to
incoming Wnt signaling, the high turnover rate of β -catenin via the SCF-β-TrCP ubiquitin
ligase complex maintains the proper balance [173].

Dysfunction in the regulatory

mechanism of β -catenin is found in many human cancers and mutated forms of β catenin which cannot be ubiquitinated by the SCF-β-TrCP ubiquitin ligase are indeed
oncogenic [168]. By enhancing down-regulation of β -catenin, β -TrCP can serve as a
tumor suppressor [174]. However, the situation is more complex as β -TrCP has also
been reported to have oncogenic potential in some situations [175, 176]. This may be
due to its role in degrading non β-catenin targets such as Claspin [177].
Paradoxically, activated forms of Ras are not only powerfully transforming, but
can also act as powerful stimulators of cell death pathways [7, 126]. Ras induced cell
death appears to be mediated, at least in part, by members of the RASSF family of
tumor suppressors, which bind Ras and function death effectors [126].
(RASSF5) was the first member of the RASSF family to be identified [9].

NORE1A
It connects

Ras to the pro-apoptotic Hippo pathway, but this does not seem to be essential for its
tumor suppressor function [129].

It also modulates p53 [10, 11], which may explain its
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ability to promote cell cycle arrest. NORE1A is expressed in most normal tissues, but its
expression is lost in many tumors due to epigenetic inactivation, loss of heterozygocity,
or deregulated proteolysis [10, 118].

NORE1A is considered a bona fide tumor

suppressor, as a hereditary genetic defect in NORE1A predisposes the human carriers
to kidney cancer [15].

However, many of the tumor suppressive functions of the

Ras/NORE1A interaction remain largely uncharacterized.
We preliminarily identified a direct interaction between NORE1A and β-TrCP in a
yeast two-hybrid screen. This suggests that either NORE1A is a substrate for SCF-β-TrCP
or, more interestingly, might connect Ras to the control of the complex. As SCF-β-TrCP
modulates the Wnt/β-catenin pathway by targeting β -catenin for degradation by the
proteasome [174], NORE1A might serve to link Ras to the control of β -catenin protein
stability and transcriptional signaling.
Following the preliminary data, I sought to determine the role of NORE1A in the
control of the SCF-β-TrCP ubiquitin ligase and Wnt/β-catenin signaling. I now show that
NORE1A forms a direct, endogenous, Ras regulated complex with β-TrCP allowing Ras
to stimulate the activity of SCF-β-TrCP towards β-catenin. The activation of the SCF-β-TrCP
ubiquitin ligase complex by Ras/NORE1A is substrate specific, as NORE1A had no
effect on SCF-β-TrCP substrate IκB. Moreover, NORE1A deficient lung tumor cells exhibit
enhanced steady state levels of β -catenin and resist the growth inhibitory effects of β TrCP. Therefore, the cellular levels of NORE1A may dictate how Ras modulates β catenin and determine the substrate profile of the SCF-β-TrCP ubiquitin ligase. β-TrCP has
been reported as an oncogene and as a tumor suppressor in different cell systems. The
levels of NORE1A may dictate the ultimate activity of β-TrCP in a cell.
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3.2 – Results

NORE1A forms a direct, endogenous, Ras regulated complex with β-TrCP
β-TrCP is the substrate recognition component of the SCF-β-TrCP ubiquitin ligase.
It is expressed as two closely related isoforms, β -TrCP1 and β -TrCP2. A yeast twohybrid screen (Myriad Genetics, Salt Lake City, UT), using full length NORE1A as bait,
identified β-TrCP1 as a potential direct binding partner. To determine if this result was
physiological, I immunoprecipitated lysates from MCF10A cells for NORE1A and
immunoblotted for the presence of β -TrCP. Figure (12a) shows that NORE1A and β TrCP could be detected in an endogenous complex.

Further studies were then

performed using exogenously expressed proteins. HEK-293 cells were co-transfected
with expression constructs for NORE1A and β -TrCP1. The cells were then lysed and
immunoprecipitated for β -TrCP1 and immunoblotted for NORE1A. The proteins could
be co-immunoprecipitated (Figure 12b).
NORE1A is a Ras effector protein, consequently I examined the role of Ras in
controlling the interaction between NORE1A and β -TrCP1 in similar experiments. The
presence of activated H-Ras in the co-transfection enhanced the association between
NORE1A and β -TrCP1 proteins (Figure 13).

These blots were under-exposed in

comparison to the blots of Figure 12b.

NORE1A promotes β-catenin degradation via β-TrCP
As β -TrCP is the substrate recognition component of the major ubiquitin ligase
complex regulating protein levels of β-catenin [167], I examined the effects of NORE1A
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Figure 12. NORE1A Forms a Protein Complex with β-TrCP - (A) Whole cell lysates
were prepared from MCF-10A cells and the protein extracts were immunoprecipitated
(IP) with anti-NORE1A for 16 hours and then immunoblotting (IB) for β -TrCP.

IgG

incubated with MCF-10A lysate and Ig/NORE1A antibody incubated with lysis buffer
serve as the negative controls. Blot of NORE1A levels is not shown due to interference
from the IgG band. MCF10A lysate serves as the positive control. (B) HEK-293 cells
were transfected with expression constructs for HA-NORE1A and GFP-β-TrCP1. Cell
lysates were immunoprecipitated (IP) with GFP-Trap® Beads (Allele Biotech, San Diego,
CA) and Immunoblotted (IB) for the presence of β-TrCP1.
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Figure 13.

Ras Regulates NORE1A Binding with β-TrCP - HEK-293 cells were

transfected with expression constructs for HA-NORE1A and GFP-β-TrCP1 in the
presence or absence of an activated form of RFP-H-Ras (12V). After 24 hours the cells
were lysed and immunoprecipitated with GFP-Trap® beads before immunoblotting. A
shorter exposure of the immunoprecipitation shows that the presence of activated H-Ras
enhances NORE1A binding to β-TrCP.
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expression on β-catenin protein stability using transient transfections performed in HEK293 cells. Co-expression of NORE1A suppressed the expression of β -catenin to subdetectable levels.

This effect was largely blocked by the 26S proteasome inhibitor

MG132 (Figure 14).

To further support the MG132 experiment, the transient

transfections of NORE1A and β-catenin were repeated once more in HEK-293 cells. 24
hours post-transfection, the cells were treated with cycloheximide. Dishes were lysed
over a time course of 24 hours and samples examined by western blot. The results
confirmed NORE1A was acting at a protein stability level (Figure 15).

In order to

determine if NORE1A and β-TrCP1 synergize to promote the degradation of β-catenin, I
partially inhibited the proteasome by adding low levels of MG132 for 6 hours. Under
these conditions, the ability of both NORE1A and β -TrCP1 to suppress β -catenin
expression was impaired rather than abolished. This allowed us to detect a synergistic
reduction in β -catenin levels when NORE1A and β -TrCP1 were transfected together
(Figure 16). Furthermore, a dominant negative form of β -TrCP1, lacking the F-Box
domain rendering it unable to confer ubiquitin onto substrates [178], blocked NORE1A
mediated degradation of β-catenin (Figure 16).
To examine the effects of Ras on the system, I included activated H-Ras in the
transfections, again with attenuation of the proteasome with low levels of MG132.
Activated Ras enhances NORE1A activity against β -catenin (Figure 17).

As further

support for the role of Ras in directly modifying the action of NORE1A, I included a
NORE1A point mutant that is defective for Ras binding in the assay (NORE1ARAMUT)
[179]. This experiment showed that the effects of Ras were due to its interaction with
NORE1A (Figure 17).
NORE1A appears to be regulating β -catenin protein levels through the
proteasome by interacting with the ubiquitin ligase, β-TrCP. If this were indeed the
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Figure 14. NORE1A Degrades β-catenin Via the 26S Proteasome - HEK-293 cells
were transfected with expression constructs for β-catenin and NORE1A. 24 hours post
transfection, the cells were trypsinized and split into two groups and allowed to rest for
an additional 24 hours.

One group was then treated with the proteasome inhibitor

MG132 for 5 hours and the other group was treated with DMSO also for 5 hours. The
cells were then lysed and immunoblotted (IB) for levels of β-catenin.
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Figure 15.

NORE1A Decreases β-catenin Protein Stability Independent of

Transcription - HEK-293 cells were transfected with vector or NORE1A and after 24
hours split into 6 dishes each. Cycloheximide was added after a further 24 hours and
dishes lysed over a time course.

Levels of β -catenin protein were measured by

Western blot. Figure shown is a representative blot of two experiments.	
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Figure 16. NORE1A Degrades β-catenin in Cooperation with β-TrCP - HEK-293
cells were transfected with expression constructs for NORE1A, β-catenin, β-TrCP1, and
a dominant negative β-TrCP (ΔFBOX) which is unable to ubiquitinate target substrates.
Low levels of MG132 were added to partially inhibit the 26S proteasome to attenuate the
system and reveal differences between weak and strong activity.
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Figure 17. Ras Regulates NORE1A Mediated Degradation of β-catenin - HEK-293
cells were transfected with expression constructs for NORE1A, a NORE1A mutant
unable to bind to Ras (RAMUT), β -catenin, and activated H-Ras. Relative levels of
GFP-β-catenin were assayed by immuno-blot. Actin serves as a loading control.
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mechanism of action, it would require β-catenin to be polyubiquitinated by β-TrCP, which
would mark it for proteasomal degradation.

To confirm this, HEK-293 cells were

transfected with expression constructs for NORE1A and GFP-β-catenin along with a HAtagged ubiquitin and treated with MG132. Incorporation of ubiquitin into GFP-β-catenin
could be detected (Figure 18).

NORE1A suppresses β-catenin signaling
Active β -catenin translocates to the nucleus where it binds the transcriptional
repressors TCF/LEF, thereby activating specific gene transcription.

To investigate if

NORE1A has any effect on β-catenin transcriptional activity, NCI-H1299 cells, null for
NORE1A expression, were transfected and stabilized with a pZIP-HA expression vector
expressing NORE1A or an empty vector control. The cells were selected in 400µg/mL
G481 solution until the selection process was complete.

Then, using an artificial

promoter sequence that is linked to the luciferase gene was used to analyze
transcriptional activity for β -catenin activity [180]. This reporter, containing a β -catenin
activation region (BAR-Luc), was co-transfected with an expression construct for β catenin and a Renilla luciferase internal control into the matched pair of NCI-H1299 cells
stably transfected with vector or NORE1A expression vector.

The NORE1A expressing

cells showed reduced β-catenin activity (Figure 19a).

Loss of NORE1A expression enhances steady state levels of β-catenin
The above results suggest that the loss of NORE1A that is so frequently found in
human tumors should uncouple Ras from the negative regulation of β-catenin. Thus, the
levels of β-catenin in a Ras driven tumor cell should inversely correlate with NORE1A
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Figure 18. NORE1A Enhances β-catenin Ubiquitination - HEK-293 cells were cotransfected with expression constructs for NORE1A, β -catenin, and a HA-tagged
Ubiquitin. 24 hours post-transfection, the cells were lysed and analyzed by Western blot
for HA incorporation into GFP- β-catenin (~120 kD).
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Figure 19.

NORE1A Suppresses Wnt Signaling - (A) NCI-H1299 cells stably

transfected with vector or NORE1A were transfected with an expression construct for βcatenin along with a β -catenin responsive luciferase reporter (BAR-Luc) and a TKRenilla internal control. Dual luciferase assays were performed and results standardized
with the Renilla readout (M1/M2). n = 2 independent experiments, error bars show
standard error, p = 0.02. (B) Immunoblot (IB) analysis confirming expression of HANORE1A. NCI-H1299 +/- for NORE1A expression shows differences in steady state
expression of β-catenin. Whole cell lysates were prepared and endogenous levels of βcatenin were analyzed by immunoblot. Quantification was performed by densitometry
using QuantityOne software by BioRad is shown above the blot as a ratio.
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expression. To test this hypothesis, I examined the levels of endogenous β -catenin in
the NCI-H1299 NORE1A +/- matched pair. These cells carry an activated Ras mutation
and undetectable levels of endogenous NORE1A [181]. Figure (19b) shows that the
NORE1A negative cells exhibited higher levels of endogenous β -catenin than the cells
stably transfected with NORE1A. As further confirmation, I transfected HEK-293 cells
with shRNA constructs against NORE1A and assayed for the levels of endogenous β catenin protein. Protein levels of β-catenin were elevated in the shRNA transfected cells
but not in the scrambled shRNA transfected cells (Figure 20a).

NORE1A differentially regulates β-TrCP targets
To determine if the effect of NORE1A on SCF-β-TrCP is a general activation or a
specific activation towards a particular sub-set of targets, a second degradation target of
β-TrCP1, IκB[182], was chosen for analysis.

HEK-293 cells were transfected with

expression constructs for IκB, β-catenin, and NORE1A. Western analysis of the protein
levels showed that while IκB levels remained the same in the presence of NORE1A,
NORE1A suppressed β-catenin (Figure 21a). IκB is a negative regulator of NFκB [183].
If NORE1A promotes its degradation, I should expect NFκB signaling to increase.
Luciferase assays using HEK-293 cells stably transfected with an NFκB luciferase
reporter showed that NORE1A does not promote the activation of NFκB (Figure 21b).

NORE1A levels dictate the biological activity of β-TrCP
β-TrCP has a range of targets and can act as an oncogene or a tumor
suppressor depending upon the particular cellular milieu [174-177].

The co-factors

determining if the net effect on growth of β-TrCP is positive or negative are not known.
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Figure 20. Loss of NORE1A Enhances Steady State β-catenin Protein Levels - (A)
HEK-293 cells were transfected with shRNA constructs against NORE1A. Endogenous
levels of β -catenin were analyzed by Western blot.

(B) Stably NORE1A shRNA

constructs were validated against endogenous NORE1A in HBEC-3KT cells.
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Figure 21.

NORE1A/β-TrCP Mediated Ubiquitination is Substrate Specific - (A)

HEK-293 cells were transfected with expression constructs for NORE1A, β-catenin, and
IκB. After 24 hours the cells were lysed and assayed for differential protein expression
by Western blot. Figure is a representative blot of at least two experiments (B). HEK293 cells stably expressing an NFκB luciferase reporter were transfected with HA-empty
vector and HA-NORE1A. A slight suppression of activity was observed due to NORE1A
but quantification showed this was not significant (p = 0.12).
experiments, error bars show standard error.
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n = 2 independent

To determine if NORE1A may be one of these factors, I transfected the NORE1A +/NCI-H1299 cell system with β-TrCP1 and selected for the marker carried by the β-TrCP1
construct. Figure (22) shows that β-TrCP1 was highly growth inhibitory in the NORE1A
positive cells but only weakly inhibitory in the NORE1A negative cells. Quantification is
shown in (Figure 23).

NORE1A is a key node in the regulation of β-catenin via Ras
Ras has been reported to exhibit both negative and positive effects on β-catenin
protein levels [184, 185]. The factors that determine the net effect of Ras on β-catenin
are not clear. To determine if NORE1A dictates the effects of Ras on β-catenin, I treated
the NCI-NCI-H1299 NORE1A +/- cell system with a farnesyl transferase inhibitor (FTI)
(Figure 24a) that inactivates Ras [186]. NCI-H1299 cells contain an activated form of
Ras, which allowed us to examine the effects of endogenous Ras activation on
endogenous β -catenin expression in a NORE1A positive or negative background. A
“normal” cell is positive for NORE1A expression and does not have an activated Ras
signaling pathway. The levels of β -catenin under these circumstances are shown in
column four of Figure 24b. In the presence of a competent activated Ras (no FTI) in
these NORE1A positive cells, the levels of β -catenin go down (column 2). However,
when I remove the FTI from NORE1A negative cells, I observed that the levels of β catenin increased (column 1) relative to the levels in the “normal” cells (column 4).
Thus, the presence or absence of NORE1A may dictate the effects of Ras, positive or
negative, on β-catenin protein levels.
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Figure 22. NORE1A/β-TrCP Cooperate to Control Cell Survival - NCI-H1299 cells
stably expressing NORE1A or an empty vector were transfected with an expression
construct for β-TrCP1 and selected with G418. Cell survival was slightly reduced in cells
expressing NORE1A or β-TrCP alone.

However, when both are co-expressed, cell

survival is greatly decreased suggesting a synergistic relationship in tumor suppression
functions.
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Figure 23. Quantification of NORE1A/β-TrCP Effects on Cell Survival - Figure 22
shows a representative experiment, Figure 23 shows quantification of live cells after 2
weeks. The data is the average to two separate assays performed in duplicate. The
error bars on the graph represent standard error with p = 0.03.
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Figure 24. Inhibition or Ras Farnesylation Impedes NORE1A Mediated β-catenin
Control - (A) NCI-H1299 cells stably transfected with NORE1A or empty vector were
treated +/- with a farnesyl transferase inhibitor for 24 hours to inhibit Ras signaling.
Whole cell lysates were harvested and probed for total levels of endogenous β-catenin.
A representative blot is shown in (A), quantification of two experiments is shown below in
(B).

Vector = Ras+/NORE1A-, NORE1A = Ras+, NORE1A+, Vector + FTI = Ras-

/NORE1A-, NORE1A + FTI = Ras-/NORE1A+.

A normal cell would be expected to be

negative for activated Ras and positive for NORE1A. Thus, bar 4 is the reference bar.
Quantification using densitometry was calculated on QuantityOne software from BioRad.
Values from two separate assays were combined for quantification. The graph shows
this data with standard error and p = 0.02.
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3.3 - Discussion

NORE1A directly binds activated Ras and serves as a pro-apoptotic Ras effector
[10, 11]. What's more, NORE1A suppresses tumor cell growth, is frequently inactivated
in human tumors, and its inactivation is implicated in a hereditary cancer syndrome [15,
126, 187]. Therefore, it is likely to serve as an important human tumor suppressor. At
one point, NORE1A was implicated in the regulation of Hippo signaling as it binds to the
MST kinases; however, further study revealed that NORE1A fails to activate their kinase
activity [10, 135]. Furthermore, deletion mutants of NORE1A that cannot interact with
MST kinases retain the ability to inhibit cell growth and suppress the tumorigenic
phenotype [129]. Thus, unknown tumor suppressor pathways independent of the classic
Hippo pathway must also be modulated by NORE1A.
β-TrCP is the substrate recognition component for the SCF-β-TrCP ubiquitin ligase
complex and exists as two closely related isoforms, β -TrCP1 and β -TrCP2. Under the
influence of Wnt signaling, it binds and regulates the degradation of the proto-oncogene
β-catenin [174]. β -catenin has a dual role in the cell serving both as a component of
adherens junctions in the cytoplasm and as a transcriptional co-regulator in the nucleus
modulating the function of the TCF/LEF transcription factors [188]. The Wnt/β-catenin
pathway plays key roles in development and tumorigenesis, and mutations in the system
leading to the excessive accumulation of β -catenin have been identified at high
frequency in human tumors [168, 188, 189].
Aberrant activation of the Ras pathway is one of the most common defects
observed in human cancers [30]. Over a decade of study has revealed multiple, subtle
links between the Ras and Wnt/β-catenin pathways. The links are complex and remain
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poorly understood as they invoke both synergistic and antagonistic relationships [164].
Indeed, Ras has been reported to suppress β -catenin levels but also to promote β catenin transcription [184, 185].

The net effect appears to be context dependent.

However, in vivo studies have confirmed that defects in the two pathways can synergize
to promote cancer [161].
Here I show that Ras promotes the binding of NORE1A to β-TrCP1, the substrate
recognition component of the SCF-β-TrCP ubiquitin ligase and this interaction promotes the
degradation of β-catenin (Figure 25). As I identified NORE1A and β- TrCP1 in a yeast
two-hybrid interaction screen, this interaction is likely to be direct. The interaction of
NORE1A with β -TrCP1 explains how Ras can negatively regulate β -catenin and how
such regulation may be defective in tumor cells that have suffered inactivation of
NORE1A. By using FTIs to inhibit the endogenous activated Ras in my NCI-H1299 cell
system, I were able to show that Ras down-regulates endogenous β -catenin protein
levels in the presence of NORE1A but enhances them in its absence. Thus, the levels
of NORE1A in a cell may play a major role in determining the net effect of Ras on β catenin. However, it is not impossible that these experiments also impacted non-Ras
farnesylated targets. So further experiments to examine the biological effects of the
Ras/NORE1A/β-TrCP1 interaction may be warranted.
At this point, the mechanism by which NORE1A specifically stimulates SCF-β-TrCP
ubiquitin ligase activity via β -TrCP1 remains unclear.

In order for substrates to be

recognized by β-TrCP, they first must be phosphorylated.

Therefore, I hypothesize

NORE1A may potentially be acting as a scaffold for other substrate regulatory
components, including GSK-3β, Axin, and APC.

Furthermore, in order for ubiquitin

ligases to function properly, the E3 component requires a complex of several proteins
that serve as substrate adapters. Thus, other potential proteins NORE1A may scaffold
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Figure 25. Diagram of the Proposed Novel NORE1A/β-TrCP Signaling Module –
Here I show my proposed Novel Ras/NORE1A/Wnt signaling pathway. I interpret my
data to suggest that this Ras/NORE1A signaling pathway activates β -TrCP towards a
subset of its substrates such as β -catenin but not IkB.

This results in differential

degradation of SCF-β-TrCP substrates by the proteasome in the presence of
Ras/NORE1A signaling.
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these E1 and E2 elements, specifically SCF (Skip/Cullin/F-Box) components, resulting in
an enhanced stabilization of a functional ubiquitin ligase complex.

Lastly, perhaps

NORE1A functions in recruiting, scaffolding, and stabilizing specific β-TrCP substrates
for ubiquitination including β-catenin, Claspin, REST, or DEPTOR, explaining the
observed altered substrate specificity of β-TrCP often found in cancer.
β-TrCP1 can act as a tumor suppressor [174], as is expected since it can serve
as a negative regulator of β -catenin, but has also been reported to exhibit oncogenic
functions in some cellular environments [175, 176]. This may be due to its effects on
substrates in addition to β -catenin. These include a range of proteins involved in cell
cycle regulation and transcriptional control such as IκB [190, 191], NFκB [192], GLI2
[193, 194], REST [195, 196], ATF4 [197], CDC25A [198, 199], CDC25B [199], and
Claspin [200, 201]. It seems likely that mechanisms exist to target β-TrCP to particular
substrates under particular conditions. NORE1A may be part of such a mechanism as it
activates β-TrCP1 towards β-catenin but not towards IκB. As I found that the ability of βTrCP1 to suppress growth of tumor cells is heavily dependent upon the presence of
NORE1A, it may be the NORE1A status of a cell that dictates whether or not β-TrCP1 is
oncogenic or tumor suppressive.

It will be interesting to determine which other

substrates NORE1A activates β-TrCP1 against.
NORE1A is not the first member of the RASSF family to be identified as binding
to β -TrCP1. A splice variant of the RASSF1A protein, RASSF1C, can also bind [202].
However, unlike NORE1A, RASSF1C acts to somehow stabilize β-catenin protein levels
and enhance β -catenin signaling.

Perhaps it acts by competing with NORE1A for

binding.
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Another pathway that RASSF family members have been associated with is the
Hippo pathway. This pathway is a major signaling mechanism involved in controlling
organ size and apoptosis [203].

The canonical Hippo signaling pathway involves a

kinase cascade where MST kinases phosphorylate LATs kinases which then act on the
transcriptional co-regulators YAP and TAZ [204]. RASSF proteins, such as NORE1A,
can bind the MST/Hippo kinases [10]; nevertheless, NORE1A does not enhance their
activity toward the Hippo pathway executors YAP and TAZ by MST/LATS
phosphorylation [135].

However, in addition to β -catenin, β -TrCP1 also binds and

regulates the stability of YAP and TAZ [205]. Interestingly, the Hippo pathway intersects
with the Wnt pathway at many levels. The first intersection discovered identified a point
of β-catenin regulation where TAZ could interact with Dishevelled disrupting GSK-3β
phosphorylation of β-catenin, effectively stabilizing Wnt signaling [206]. Additionally, the
Hippo pathway has been shown to enhance transcription of Wnt target genes by
upregulating the ability of β-catenin to transcribe target genes [207].

Finally, a recent

study demonstrated that YAP and TAZ are required elements for recruitment of β-TrCP
to the β-catenin destruction complex and are degraded together with β-catenin [208].
Therefore, the interaction of NORE1A with β -TrCP1 may allow NORE1A to invoke
powerful non-canonical Hippo pathway regulation outside of the MST1/2 kinases. This
may prove to be a potent additional mechanism where the RASSF family proteins
contribute to growth and survival control.
Thus, I identify a function for NORE1A acting as a Ras activated control element
for β-TrCP that stimulates the ubiquitin ligase complex towards specific targets. These
results may explain, mechanistically, many of the apparent contradictions in the
relationship between the Ras and the Wnt/β-catenin pathways.
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CHAPTER IV

NORE1A INTERACTS WITH GSK-3β ENHANCING
β-CATENIN PHOSPHORYLATION

4.1 - Introduction

Signaling by the Wnt family of proteins is one of the core cellular mechanisms
that coordinate cell proliferation, cell polarity, and tissue homeostasis [14, 209].
Mutations in the Wnt pathway are often associated with human birth defects and cancer
[203]. The most studied aspect of the Wnt signaling mechanism is centered on the
regulation

of

the

transcriptional

co-activator, β -catenin,

developmental genetic expression programs [209].

which

controls

key

In normal tissue growth and

development, the cell requires coordination between signal transduction pathways such
as the Hippo and Wnt/β-catenin pathways. In normal cells receiving Wnt signal, Wnt
promotes growth and proliferation [210]. However, in cancer, Wnt signaling is typically
corrupted into an Wnt signal independent “on” state as a result of one of several genetic
mutations, most of which center around proteasomal regulation of β-catenin [210].
In the canonical Wnt/β-catenin signaling pathway, β -catenin serves as both a
nuclear transcriptional co-regulator and core component of adherens junctions [166].
The cellular mechanism involved in the control of β-catenin is centered on the presence
or absence of Wnt ligand.

In the absence of Wnt ligand signaling, a multi-protein
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complex consisting of APC, Axin, and GSK-3β, phosphorylates β -catenin.

The

phosphorylation is a required step for recognition and binding by β -TrCP, the E3
component of the SCF-β-TrCP ubiquitin ligase complex. SCF-β-TrCP mediated ubiquitination
of β -catenin results in its rapid degradation by the 26S proteasome [211]. When Wnt
ligand activates this pathway, the GSK-3β phosphorylation complex is disrupted by
Disheveled family proteins allowing for unphosphorylated β -catenin levels to quickly
increase in the cytoplasm and translocate to the nucleus [168]. Nuclear β -catenin
functions as a coactivator for transcription factors of the TCF/LEF family, modulating
genes involved in growth and survival [168].

While cells constitutively synthesize β -

catenin to maintain a ready response to incoming Wnt signaling, the very quick turnover
rate of β -catenin maintains a proper signaling balance [173].

Dysfunction in the

regulatory mechanism of β -catenin has been described in many human cancers and
mutated forms of β -catenin which cannot be phosphorylated by GSK-3β are potently
oncogenic [168].
In the previous chapter, I characterized a novel, direct interaction between
NORE1A and β-TrCP, the E3 component of a SCF ubiquitin ligase complex [212]. This
Ras mediated complex effectively regulated β-catenin protein stability and established a
novel role for NORE1A in the regulation of oncoprotein stability [212]. Accordingly, loss
of NORE1A expression resulted in an increase in steady state levels of β -catenin and
resistance to β -TrCP mediated growth inhibitory effects [212]. Nonetheless, before β catenin can be recognized and ubiquitinated by β-TrCP, it first must be phosphorylated
by GSK-3β. NORE1A has no known enzymatic activity and appears to function in cells
as a scaffolding protein [13, 130, 212, 213]. Perhaps a potential function of NORE1A in
the regulation of β -catenin (Wnt pathway) works by scaffolding GSK-3β to β -TrCP
resulting in a more efficient protein regulatory mechanism. Correspondingly, loss of
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NORE1A would remove a key negative Ras mediated regulatory element and may
explain why Ras and Wnt are often found co-activated in many human cancers [214].
To determine if NORE1A is determining factor governing the effects of Ras on
Wnt signaling, a series of studies were undertaken. Here I now show that NORE1A
forms an endogenous complex with GSK-3β.

This novel protein/protein interaction

between NORE1A and GSK-3β results in a coordinated and enhanced GSK-3β
phosphorylation of β -catenin. I also show that when cells were treated with LiCl2, a
specific inhibitor of GSK-3β activity, NORE1A lost the ability to enhance β -catenin
degradation.

Moreover, a triple point mutant of NORE1A that fails to bind GSK-3β is

deficient in suppressing β -catenin.

The NORE1A/GSK-3β mechanism appears to

operate independently of Ras signaling and more than likely has much broader
implications with respect to cellular tumor suppression.

Furthermore, this novel

interaction provides key insight into RASSF tumor suppression control via NORE1A.

4.2 - Results

NORE1A forms and endogenous complex with GSK-3β
I previously published that NORE1A can negatively regulate β-catenin protein levels by
interacting with the E3 ubiquitin ligase, β -TrCP [212].

However, NORE1A has been

recently shown to interact with kinases involved in Hippo and p53 signaling [14, 133].
Thus the potential exists for NORE1A to interact with kinases involved in β -catenin
regulation. While β-catenin is regulated by a dual-kinases system consisting of CK1 and
GSK-3β, the latter actually marks β-catenin for recognition and ubiquitination by β-TrCP
[215].

Accordingly, I sought to determine if NORE1A and GSK-3β interact.
91	
  
	
  

	
  

First,

HEK293T cells were transfected with expression constructs expressing HA-GSK-3β and
a GFP-NORE1A along with an activated H-Ras(12Val). Cells were lysed 24 hours posttransfection and immunoprecipitated against the GFP-epitope tag. NORE1A was found
in complex with GSK-3β and this interaction did not seem to be affected by the presence
of Ras (Figure 26). To determine if this result was physiological, MCF-10A cells were
lysed and an antibody against GSK-3β was used to immunoprecipitate GSK-3β.
NORE1A was again found in an endogenous complex (Figure 27).

NORE1A enhances phosphorylation of β-catenin.
Since NORE1A and GSK-3β were found in an endogenous complex, I next
sought to determine if NORE1A enhances phosphorylation of β -catenin. H1299 cells,
null for NORE1A expression, were transfected with either an empty vector or pZIP-HANORE1A. Transformants were selected using G418 yielding a stable population that
was +/- for NORE1A expression.

Using an antibody against specific GSK-3β

phosphorylated residues of β -catenin (Ser33/37/Thr41), cell lysates from H1299 cells
that were +/- for NORE1A were analyzed by Western blot to see if NORE1A enhances
GSK-3β mediated phosphorylation of β -catenin. In the lysates from cells expressing
NORE1A,

there

was

a

substantial

increase

in

phosphorylated β -catenin

(Ser33/37/Thr41) when compared to lysates expressing empty pZIP-HA-vector (Figure
28).

	
  
92	
  
	
  
	
  

	
  
	
  
	
  
	
  

	
  
	
  
Figure 26. NORE1A Complexes with GSK-3β - HEK-293T cells were transfected with
expression constructs for NORE1A, GSK-3β, and a constitutively activated H-Ras
(12Val). NORE1A was immunoprecipitated using anti-GFP agarose beads and levels of
bound GSK-3β was analyzed by Western blot. The results of this experiment show that
NORE1A complexes with GSK-3β and this interaction does not appear to be affected by
Ras.
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Figure 27. Endogenous Immunoprecipitation of NORE1A and GSK-3β - Whole cell
lysates were prepared from

MCF-10A

cells and the purified extracts were

immunoprecipitated (IP) with anti-GSK-3β for 16 hours and then immunoblotted (IB) for
NORE1A. IgG incubated with MCF-10A lysate and Ig/GSK-3β antibody incubated with
lysis buffer serve as the negative controls.

MCF-10A lysate serves as the positive

control. NORE1A is detected in an endogenous complex with GSK-3β.
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Figure 28.

NORE1A Enhances β-catenin Phosphorylation on GSK-3β Target

Residues - H1299 cells, null for NORE1A expression, were transfected with either pZIP
vector or pZIP-HA-NORE1A. Transformants were selected using G418 yielding a stable
population that is either +/- for NORE1A expression. Cells were lysed and analyzed on
a Western blot for phosphorylated β-catenin. In the cells expressing NORE1A, there is a
marked increase in levels of phosphorylated β-catenin on GSK-3β target residues.
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Lithium Chloride prevents NORE1A mediated β-catenin degradation.
To determine if NORE1A is using GSK-3β or another kinase to phosphorylate
and drive β-catenin degradation, I chose Lithium Chloride to specifically inhibit GSK-3β
phosphorylation activity [216].

HEK-293 cells were transfected with expression

constructs expressing β-catenin paired with either an empty vector or HA-NORE1A. As
expected, in the presence of NORE1A, levels of β-catenin are difficult to detect (Figure
29). However, when LiCl2 is added to the cell media for 24 hours, NORE1A loses the
ability to suppress β-catenin protein levels when analyzed by Western blot (Figure 29).
NORE1A can bind several cellular kinases, including HIPK2 [14]. HIPK2 is known to be
able to regulate β-catenin as well [217]. However, LiCl2 specifically inhibits GSK-3β and
does not disrupt HIPK2 kinase activity [218].
NORE1A

is

in

fact

working

through

Thus, this result helps confirm that

GSK-3β

and

not

mediating β -catenin

phosphorylation via other kinases like HIPK2.

Disruption of the NORE1A/GSK-3β interaction suppresses the ability of NORE1A
to downregulate β-catenin.
To further support the Lithium Chloride data, I sought to develop a point mutant
of NORE1A that disrupted its binding to GSK-3β. Using fragment mapping and site
directed mutagenesis, a triple point mutant of NORE1A was developed mutating the 9294 residues from Arg to Ala.

HEK-293T cells were transfected with expression

constructs for GSK-3β paired with empty vector, NORE1A, and the triple point mutant
(NORE1A 92-94A mutant). 24 hours post-transfection, the cells were lysed and the cell
lysate was immunoprecipitated using GFP-conjugated agarose beads. The assay was
then analyzed on a Western blot where GSK-3β was found to complex strongly with
NORE1A; however, GSK-3β failed to complex with the mutant NORE1A (Figure 30).
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Figure 29. Inhibition of GSK-3β Kinase Activity Blocks NORE1A’s Effects on βcatenin - HEK-293 cells were transfected with expression constructs expressing
NORE1A and β-catenin. 24 hours post-transfection, the cells were treated with LiCl2 for
another 24 hours. LiCl2 is known to be an effective inhibitor of GSK-3β kinase activity.
In the cells treated with LiCl2 at a final concentration of 10mM, NORE1A mediated
downregulation of β-catenin is impaired. This result suggests that NORE1A is regulating
β-catenin protein levels in by enhancing GSK-3β kinase activity.
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Figure 30. Development of NORE1A Point Mutant that Fails to Bind GSK-3β - In
order to further understand the cellular implications of the NORE1A/GSK-3β interaction,
mutations were made in NORE1A focused on disrupting its interaction with GSK-3β.
Deletion mutagenesis suggested that potential GSK-3β binding region rested in the 9294 amino acid residues of NORE1A. These residues were mutated to Alanine residues
via PCR mutagenesis.

Then HEK-293T cells were transfected with expression

constructs for GSK-3β and either wild-type NORE1A or the mutant NORE1A (92-94A).
Cells were lysed 24-hours post-transfection and immunoprecipitated.

Wild-type

NORE1A was found in complex with GSK-3β. However, the mutant NORE1A (92-94A)
failed to bind GSK-3β.
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The mutant NORE1A was then employed to see if disruption of the interaction between
NORE1A and GSK-3β affects the observed downregulation of β-catenin. HEK-293 cells
were

transfected

with

expression

constructs

expressing

either β -catenin

and

subsequently paired with an empty vector, wild type NORE1A, or the mutant NORE1A
92-94A. Results show the wild type NORE1A suppressed β-catenin protein levels, while
the mutant NORE1A (92- 94A) was unable to suppress them (Figure 31). This is in
agreement with the LiCl2 experiment and again supports the idea that NORE1A is
indeed coordinating GSK-3β to regulate β-catenin.

4.3 - Discussion

The evolutionarily conserved Wnt signaling pathway is a vital signaling
mechanism controlling a wide range of cellular processes including growth,
development, tissue repair, and organogenesis [219]. In canonical Wnt signaling, Wnt
ligands activate the pathway by binding to the Frizzled receptor [14]. Activation of this
receptor stabilizes cellular levels of β-catenin and results in the formation of a
transcriptional complex containing a DNA-binding factor known as lymphocyte enhancer
factor (Lef), T-cell factor (Tcf) driving transcription of a set of growth and development
genes [13]. However, a very intricate set of events is required before this complex can
be stabilized and begin transcription.

Wnt signaling involves the inhibition of a

constitutively active degradation mechanism that keeps cytosolic “signaling” pool of β catenin at low levels [13]. Disruption of this degradation complex allows β-catenin levels
to quickly increase where it can then enter the nucleus to drive transcription of the
Tcf/Lef family genes [13]. Conversely, in the absence of Wnt signaling, cytosolic β-
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Figure 31.

Disruption of NORE1A/GSK-3β Impairs NORE1A Degradation of β-

catenin - HEK-293 cells were transfected with expression constructs expressing β catenin paired with empty vector, wild-type NORE1A, and the mutant of NORE1A that
fails to bind GSK-3β (NORE1A92-94A). In cells expressing β-catenin with empty vector,
protein levels of β-catenin are high. As expected, in the presence of wild-type NORE1A,
levels of β-catenin are suppressed. Intriguingly, when β-catenin was co-expressed with
the 92-94A mutant, β -catenin was not degraded and appears to be stabilized to an
extent suggesting that the 92-94A mutant may be acting as a dominant negative with
regard to β-catenin proteasomal regulation.
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catenin is rapidly degraded through ubiquitin mediated proteasomal degradation. The
kinases CKI and GSK-3β play central roles in controlling β -catenin levels [13]. Yet,
studies show that cells require very strict coordination in regulating β -catenin protein
levels to maintain homeostasis, and disruption of these mechanisms is often oncogenic
[168].
Glycogen synthase kinase 3 (GSK-3β) is a serine/threonine kinase that is an
important component of numerous signaling pathways involved in the regulation of cell
survival, protein synthesis, glycogen metabolism, cell mobility, and proliferation [220]. In
addition to these functions, GSK-3β also negatively regulates many proto-oncogenic
proteins and cell cycle regulators via the ubiquitin proteasome system [221].

When

considering the broad range of oncogenic targets, it is easy to assume that GSK-3β
functions to suppress tumorigenesis and indeed several studies support the view that
GSK-3β functions as a tumor suppressor.

Oddly enough, unlike most other protein

kinases, GSK-3β is constitutively active.

Thus, other factors that affect its proper

function, including the presence or absence of scaffolding molecules, must exist to
regulate target acquisition and are likely key in determining the oncogenic potential of a
cell.
Since GSK-3β negatively regulates many proto-oncogenic proteins and cell cycle
regulators, a tumor suppressive role makes perfect sense [221]. However, some studies
suggest that GSK-3β may actually promote tumorigenesis and cancer development as
GSK-3β over expression has been observed in human ovarian, colon, and pancreatic
cancers [222]. Hence, it remains controversial whether GSK-3β is a tumor suppressor
or tumor promoter. Therefore, the role GSK-3β plays in cancer is likely complex and
may be dependent on specific cellular circumstances or perhaps the presence or
absence of cooperating tumor suppressor proteins like NORE1A.
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GSK-3β regulates many diverse substrates and signaling pathways, and the
mechanisms that determine its tumor suppressive function are indeed complicated. One
of the better-characterized roles of GSK-3β on tumor suppression is centered on its
control

of β -catenin,

the

terminal

executor

of

the

Wnt

signaling

pathway.

Phosphorylation of β -catenin by GSK-3β targets it for ubiquitination by the substrate
recognition protein β-TrCP and subsequent proteasomal degradation. Activation of Wnt
signaling disrupts GSK-3β mediated phosphorylation of β-catenin allowing cellular levels
of β -catenin to increase. As β-catenin levels climb, the protein moves to the nucleus
where it co-activates transcription of genes of the TCF/LEF gene group.
Over 15 years of study has revealed multiple, subtle links between the Ras and
Wnt/β-catenin pathways. The links are complex, occur at multiple levels, and remain
poorly understood as they invoke both synergistic and antagonistic relationships [164].
Ras has been reported to suppress β -catenin levels but it has also been reported to
promote β-catenin mediated gene transcription [184, 185]. The net effect appears to be
situationally dependent. While the antagonistic effects are likely not tumorigenic, the
synergistic effects likely are tumorigenic and in vivo studies confirmed that defects in the
two pathways can promote cancer [161]. Data shown thus far supports my original
hypothesis names NORE1A has the potential to be the link that determines whether Ras
can activate or suppress Wnt.
In the previous chapter, I showed how Ras signaling enhances the binding of
NORE1A to β-TrCP, enhancing ubiquitination of specific substrates regulated by the βTrCP ubiquitin ligase [212]. β -TrCP is the E3 substrate recognition component for the
SCF-β-TrCP ubiquitin ligase complex and is known to be the major ubiquitin ligase involved
in the regulation of β-catenin protein levels. I now present evidence that NORE1A has
deeper involvement in this protein regulatory mechanism.
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Here I show a novel

interaction between NORE1A and GSK-3β and demonstrate that NORE1A can activate
the kinase activity of GSK-3β towards a specific substrate of the Wnt pathway, β catenin. NORE1A appears to be working exclusively through the GSK-3β kinase as a
specific GSK-3β kinase inhibitor, LiCl2, blocks the ability of NORE1A to suppress β catenin protein levels. Furthermore, a mutant of NORE1A that fails to bind GSK-3β is
deficient in properly regulating β -catenin protein levels. Taken together, these results
suggest that NORE1A is working to control Wnt signaling by coordinating both
phosphorylation and ubiquitination of β-catenin (Figure 32). NORE1A and GSK-3β play
an essential role in the Ras mediated regulation of Wnt/β-catenin signaling and loss of
NORE1A shifts the relationship between Ras and Wnt from antagonistic to protagonistic
resulting in enhanced tumorigenesis.
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Figure 32. Enhanced Diagram of the Proposed NORE1A/GSK-3β/β-TrCP Signaling
Complex - This schematic, depicting a novel NORE1A mediated protein regulatory
complex, demonstrates how I hypothesize NORE1A to function as a scaffolding
molecule in this protein regulatory complex. NORE1A binds and enhances both GSK-3β
and β-TrCP activity on the specific substrate, β-catenin. Perhaps the reason for this lies
in the potential for NORE1A to be scaffolding the individual elements of this complex
together. Bringing the kinase and ubiquitin ligase in close proximity may determine the
speed and success of target substrate regulation.
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CHAPTER V

NORE1A SPECIFICIALLY REGULATES TAZ INDEPENDENTLY OF HIPPO BY
SCAFFOLDING GSK-3β TO β-TRCP

5.1 - Introduction

The Hippo signaling pathway is an evolutionarily conserved signaling mechanism
that regulates organ size by controlling the cell cycle, regulating cell proliferation, and
activating apoptosis [223, 224]. In tissue growth and development, the cell requires
strict coordination of signal transduction pathways.

The Hippo pathway was first

believed to be important in human cancers when observations made in Drosophila
melanogaster tissues containing Hippo mutations are transformed [225]. More recent
experiments using mice and studies involving the screening of human cancer genomes
have validated this belief by identifying that mutations in Hippo signaling are indeed
oncogenic [226, 227]. Despite recent progress, full understanding of the Hippo pathway
remains incomplete [228]. While the conserved canonical Hippo signaling pathway has
been established, potentially important variations on this cascade await characterization
in mammals [228]. Furthermore, additional levels of Hippo regulation potentially exist as
it is likely that several upstream inputs remain to be discovered and defined [228].
The Hippo pathway consists of a signaling cascade of proteins that cooperate in
controlling growth and development stimuli. Most of the key pathway regulation occurs
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in a small core component of the canonical Hippo pathway. These components include
the protein kinases LATS1/2 and MST1/2, which function as members of a kinase
cascade [229].

These kinases work to phosphorylate and degrade the terminal

elements of the Hippo pathway, the transcriptional co-activators YAP and TAZ [230,
231]. YAP and TAZ bind to and co-activate transcription factors including TEAD and βcatenin to activate transcription of genes required for cell survival and proliferation [207,
232, 233]. In recent years, the Hippo signaling pathway has gained increasing attention
as mutations in the upstream regulatory components leading to the ineffective regulation
of YAP/TAZ have been identified in human cancers [234]. Both YAP [235, 236] and TAZ
[237, 238] exhibit oncogenic properties and elevated TAZ expression can be found in a
wide variety of aggressive cancers [239].
The Hippo pathway cross-talks with several other signaling pathways such as
Notch, Wnt, Sonic hedgehog (Shh) [240]. However, there is another pathway that can
regulate Hippo and has some of the most powerful impacts on cellular oncogenesis, and
that pathway is the Ras signaling pathway. This establishes an interesting paradigm
where you have two molecular pathways, one that causes cancer and one that protects
against it, signaling through each other.

Ras has been shown to stimulate both

oncogenic transformation and apoptosis through activation of a variety of effectors [241].
While the pro-transformation elements of Ras signaling are fairly well characterized, the
pro-apoptotic mechanisms that protect the cell from hyper-active Ras stimulation are far
less understood.

A key breakthrough occurred when it was discovered that Ras

modulates pro-apoptotic MST signaling activity via the RASSF family of proteins,
canonically activating the Hippo pathway [241].
RASSF1A, a member of the RASSF family, was shown to bind MST and activate
the Hippo apoptotic pathway [133, 135]. Under Ras stimulation, RASSF1A stimulates
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MST kinase activity as well as binding to its substrate, LATS [242, 243]. Activation of
the LATS kinase in turn leads to the phosphorylation of YAP [241]. LATS has been
shown to phosphorylate YAP on multiple residues, each having different regulatory
functions [244]; however, one of the key residues in apoptotic signaling involves
phosphorylation of YAP on S127, which leads to its cytosolic sequestration and
subsequent degradation [244].
Several other members of the RASSF family also have the potential bind MST
using a special conserved domain termed the SARAH (Salvador/RASSF/Hippo)
domain[133]. Thus, it was not surprising when NORE1A (RASSF5) was found to bind
the MST kinases [10]. Initially, it was believed that NORE1A, much like RASSF1A,
activated the MST kinases [10]. However, upon further study, this initial finding has
become somewhat controversial [135]. The aforementioned study showed that while
NORE1A indeed binds, MST, there was no evidence found linking NORE1A to the
activation of its kinase activity [135]. Furthermore, a mutant of NORE1A that fails to
complex with MST still powerfully functions as a tumor suppressor [129]. Therefore, in
contrast to RASSF1A, NORE1A likely fulfills its function as a tumor suppressor
independently of canonical Hippo signaling.
In canonical Hippo signaling, YAP and TAZ are usually considered to be coregulated. When the upstream kinase module of MST1/2 and LATS1/2 is activated,
YAP and TAZ are equally phosphorylated leading to their inhibition of transcriptional
activity

through

14-3-3

mediated

cytoplasmic

sequestration

and

proteasomal

degradation [225]. However, the regulation of the two terminal Hippo pathway executors
is not identical. While YAP and TAZ are co-regulated canonically by Hippo activated
LATS-dependent phosphorylation, it was later discovered that TAZ has multiple
phosphorylation sites recognized by a variety of other cellular kinases that can result in
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different mechanisms of regulation [205]. While LATS phosphorylation of TAZ at S89
results in cytoplasmic sequestration, phosphorylation by the same kinase at S311 results
in recognition and ubiquitination by the SCF-β-TrCP ubiquitin ligase complex leading to its
degradation in the 26S proteasome [205].

Furthermore, TAZ contains another N-

terminal phosphodegron that is unique and not found in YAP [245]. This phosphodegron
at S58/62 is recognized by the GSK-3β protein kinase, activating an additional
recognition site for β -TrCP ubiquitination [18]. While the same SCF E3 component is
involved in recognition of both the C-terminal LATS phosphodegron and the N-terminal
GSK-3β phosphodegron, these mechanisms are distinctly different and either one is
found to be sufficient to induce TAZ degradation [18].
In Chapter III, I identified and characterized a direct interaction between
NORE1A and β-TrCP, the E3 component of a SCF ubiquitin ligase complex [212]. This
Ras mediated complex effectively regulated β -catenin protein stability and provided
insight on how NORE1A functions as an effective scaffolding protein [212]. Accordingly,
loss of NORE1A expression resulted in an increase in steady state levels of β -catenin
and resistance to β-TrCP mediated growth inhibitory effects [212]. During my studies, I
noticed that NORE1A expression appeared to specifically suppress the stability of TAZ
rather than YAP.

As TAZ, and not YAP, is specifically regulated by a GSK-3β

phosphodegron/SCF-β-TrCP ubiquitination process, I hypothesized that NORE1A might
act as a Ras regulated scaffold to modulate the action of GSK-3β and SCF-β-TrCP on TAZ,
as well as β-catenin.
Here I now show NORE1A regulates TAZ outside of canonical Hippo signaling.
My data shows that NORE1A is found in an endogenous complex with GSK-3β and acts
as a Ras regulated scaffold for GSK-3β and β-TrCP. This allows NORE1A to promote
the GSK-3β dependent degradation of TAZ independently of the canonical Hippo
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pathway.

Moreover, this property is an essential component of NORE1A tumor

suppressing activity, as a point mutant of NORE1A that cannot interact with GSK-3β is
defective for suppression of TAZ, and defective for the ability to promote senescence
[14].
Thus I identify a novel mechanism by which Ras can control TAZ levels
independently of the canonical Hippo pathway. Moreover, as the role of GSK-3β in
cancer development is now known to be extensive [246], the identification of a
Ras/NORE1A/GSK-3β signaling pathway may reveal a novel function of Ras.

5.2 - Results

NORE1A Differentially Regulates Hippo pathway endpoints YAP and TAZ
NORE1A was originally thought to regulate cellular apoptosis by binding and
activating the MST1/2 kinases, resulting in an induction of Hippo apoptotic signaling [10].
However, another study would go on to show that NORE1A does not activate MST1/2
kinase cascade [135]. In response to these opposing reports, I sought to determine if
NORE1A had any effect on the stability of YAP and TAZ, thereby modulating Hippo
pathway signaling. To investigate this, HEK-293 cells were transfected with mammalian
expression plasmids expressing YAP or TAZ paired with either NORE1A or an empty
vector control.

Here I observed YAP stability was not affected by the presence of

NORE1A (Figure 33). However, TAZ protein levels were powerfully suppressed in the
presence of NORE1A demonstrating that NORE1A differentially regulates YAP and TAZ
(Figure 33).
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Figure 33. NORE1A Differentially Regulates YAP and TAZ - NORE1A differentially
regulates YAP and TAZ. To determine whether NORE1A regulated YAP and TAZ in
similar manners or with similar specificity, I took HEK293 cells and transfected them with
expression constructs expressing YAP or TAZ paired with an empty vector or a construct
expressing NORE1A.

24 hours post-transfection, the cells were lysed and the total

levels of YAP and TAZ were examined by Western blot.

NORE1A strongly

downregulated TAZ protein levels, yet did not have a negative effect on the stability of
YAP.
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Knockdown of NORE1A expression leads to enhanced steady state levels of TAZ
To confirm the result from figure 33 where NORE1A suppresses TAZ protein
levels, I tested whether knocking down NORE1A had the reverse effect on endogenous
steady state TAZ. To achieve this, HEK293 cells were transfected with two different
shRNA constructs against NORE1A [14, 212]. 48-hours post-transfection, the cells were
lysed and analyzed on a Western blot for levels of endogenous TAZ. In the cells where
NORE1A was suppressed, there was a substantial increase in steady state levels of
TAZ (Figure 34).

Lithium Chloride treatment blocks NORE1A mediated down-regulation of TAZ
In addition to GSK-3β, NORE1A has been reported to interact with the MST1/2
kinases [133].

These kinases can also mark TAZ for degradation.

So I sought to

determine whether NORE1A was working through GSK-3β by using a specific GSK-3β
inhibitor, LiCl2 [218, 247]. HEK-293 cells were transfected with a construct expressing
TAZ paired with either an empty vector or a construct expressing NORE1A. 24 hours
post-transfection, the transfected cells were split and treated with either LiCl2 or water,
which served as the carrier solution. 24 hours after treatment with the GSK-3β inhibitor,
the cells were lysed and the cell lysates were examined by Western blot. As expected,
in the absence of LiCl2, NORE1A effectively suppresses TAZ protein levels. However, in
the presence of LiCl2, the ability of NORE1A to suppress TAZ was markedly reduced
suggesting that NORE1A is indeed working via GSK-3β to suppress TAZ protein levels
(Figure 35).
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Figure 34. Knockdown of NORE1A Results in Increased Steady-State TAZ Levels To confirm the over-expression data where NORE1A suppressed TAZ protein levels, I
sought to determine whether knockdown of NORE1A would impair the cell’s ability to
properly regulate the growth and survival regulator, TAZ. HEK293 cells were transfected
with shRNA constructs against NORE1A and lysed 48-hours post-transfection, and the
cell lysates were examined by Western blot. In the cells where NORE1A was knocked
down, endogenous levels of TAZ are elevated.
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Figure 35. Lithium Chloride Impairs the Ability of NORE1A to Regulate TAZ - HEK293 cells were transfected with expression constructs expressing NORE1A and TAZ. 24
hours post-transfection, the cells were treated with LiCl2 at a final concentration of 10mM
for another 16 hours.

LiCl2 is known to be an effective inhibitor of GSK-3β kinase

activity. In the cells treated with LiCl2, NORE1A mediated downregulation of TAZ is
impeded.

This results suggests that NORE1A is regulating TAZ protein levels in

coordination with GSK-3β.
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Disruption of the NORE1A/GSK-3β interaction suppresses the ability of NORE1A
to down-regulate TAZ independently of Hippo (MST)
To confirm the Lithium Chloride data suggesting that NORE1A is regulating TAZ
independently of canonical Hippo signaling (MST), I went back and employed the mutant
of NORE1A that lost the ability to bind GSK-3β (NORE1A92-94A mutant). HEK-293T
cells were transfected with expression constructs for GSK-3β paired with empty vector,
NORE1A, and the triple point mutant, NORE1A92-94A mutant. GSK-3β was found to
complex strongly with NORE1A; however, GSK-3β failed to complex with the mutant
NORE1A (Figure 30). This mutant does not, however, disrupt binding to MST, allowing
for us to specifically isolate NORE1A/GSK-3β functions (Figure 36) [14].
Moving further, in addition to being regulated by GSK-3β, TAZ is canonically
regulated by Hippo signaling where the cellular levels of TAZ protein are suppressed by
activation the MST/LATS kinase cascade. Like other RASSF family members, NORE1A
has the ability to bind the MST1/2 kinases [133]. However, this may not result in their
activation [135]. Thus, I sought to more conclusively determine whether NORE1A is
working through MST1/2 kinases (Hippo) or through the GSK-3β kinase, or perhaps both
MST1/2 and GSK-3β to regulate TAZ.

To eliminate Hippo components, I used a

NORE1A deletion mutant lacking the SARAH motif which cannot bind MST kinases [9].
To confirm that the deletion of the SARAH motif disrupted MST1/2 binding to NORE1A,
HEK-293T cells were transfected with expression constructs expressing Myc-MST along
with an empty vector, GFP-NORE1A, or the truncation mutant GFP-NORE1AΔSARAH.
Cells were lysed 24 hours post-transfection and immunoprecipitated against the GFP
epitope tag. MST was found in a complex with NORE1A, however, when NORE1A
loses the SARAH domain, binding to MST is ablated (Figure 37).

After it was

determined that this truncation mutant failed to bind MST, I wanted to see if it retained
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Donninger et al., 2015

Figure 36. Wild-Type NORE1A and the 92-94A Mutant Complex with MST - TAZ
can be regulated by both GSK-3β and MST kinases.

Figure 30 showed that the

NORE1A92-94A mutant failed to bind GSK-3β and I needed to know whether this
mutation also disrupted the ability of NORE1A to bind MST.

HEK-293T cells were

transfected with expression constructs expressing NORE1A, the 92-94A mutant, and
MST.

Whole cell lysates were immunoprecipitated by GFP-agarose beads and the

experiment shows that NORE1A and the 92-94A mutant both bind MST.
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Figure 37. Removal of the NORE1A-SARAH Domain Disrupts NORE1A/MST
Binding - To isolate the effects of the NORE1A/MST interaction, I sought to develop a
mutant of NORE1A that fails to complex with MST. NORE1A is known to associate with
MST via the SARAH (Salvador/RASSF/Hippo) domain. I removed this domain from the
protein and performed a co-immunoprecipitation to confirm that removal of the SARAH
domain disrupted the ability of NORE1A and MST to bind.

HEK-293T cells were

transfected with expression constructs expressing NORE1A, the ΔSARAH, and MST1.
Cells were immunoprecipitated after 24 hours and the IP was analyzed by Western blot.
I confirmed that removal of the SARAH domain disrupted the ability of NORE1A to form
a protein complex with MST.
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binding to GSK-3β.

HEK-293T cells were transfected with expression constructs

expressing HA-GSK-3β paired with an empty vector, GFP-NORE1A, and GFPNORE1AΔSARAH.
immunoprecipitated.

The

cells

were

lysed

24

hours

post-transfection

and

While the removal of the SARAH domain disrupted NORE1A

binding to MST, it did not affect its binding to GSK-3β (Figure 38).
These mutants of NORE1A were then employed in an experimental system
allowing investigation of the relative importance of the interactions between NORE1A,
MST, and GSK-3β to down-regulate TAZ. HEK-293 cells were transfected with
expression constructs expressing HA-TAZ paired with a GFP-vector, GFP-NORE1A,
GFP-NORE1A92-94A, or GFP-NORE1AΔSARAH. The cells were lysed 24 hours posttransfection and levels of TAZ were analyzed by Western blot. Agreeing with previous
results, the wild-type NORE1A strongly suppressed TAZ protein levels and the mutant of
NORE1A that failed to complex with GSK-3β also failed to down-regulate TAZ protein
levels (Figure 39). Furthermore, the mutant of NORE1A that retains binding to GSK-3β
and not MST still effectively regulates TAZ protein levels. Thus, NORE1A can regulate
TAZ outside of canonical Hippo signaling operating through GSK-3β instead of MST1/2
(Figure 39).

NORE1A suppresses TAZ transcriptional co-activation via GSK-3β
Data presented thus far shows that NORE1A powerfully suppresses TAZ protein
stability.

Thus, I sought to determine whether this suppression also resulted in a

suppression of TAZ mediated TEAD promoter activity. To answer this, I performed a
series of luciferase assays using a TEAD-promoter reporter construct (TEAD-Luc).
HEK-293 cells were transfected with expression constructs expressing HA-TAZ and the
TEAD-Luc reporter along with an empty vector, NORE1A, NORE1A92-94A, and
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Figure 38. NORE1A-ΔSARAH Mutant Retains Binding with GSK-3β - HEK-293T
cells were transfected with expression constructs expressing wild-type NORE1A and the
truncation mutant lacking the SARAH domain with GSK-3β.

While the SARAH-less

NORE1A failed to bind MST (Figure 37), data shown here shows that it still complexes
with GSK-3β similarly to wild-type NORE1A

118	
  
	
  
	
  

Figure 39. NORE1A Regulates TAZ Independently of Hippo (MST) Via GSK-3β Now that I have developed two mutants of NORE1A that each bind only one of the
kinases that regulate TAZ, I sought to see if I could identify whether NORE1A was
regulating TAZ via GSK-3β, MST, or both.

HEK293 cells were transfected with an

expression construct expressing TAZ paired with wild-type NORE1A, the 92-94A mutant
(fails to bind GSK-3β), or the ΔSARAH (fails to bind MST).

I found that wild-type

NORE1A and the mutant that does not complex with MST both strongly suppressed TAZ
protein levels. However, the mutant of NORE1A that fails to complex with GSK-3β also
failed to suppress TAZ. Taken together, this supports my hypothesis that NORE1A
regulates TAZ specifically via GSK-3β.
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NORE1AΔSARAH.

Wild-type NORE1A suppressed TAZ mediated TEAD-promoter

activation (Figure 40). Additionally, the triple point mutant of NORE1A (92-94A) that
failed to bind GSK-3β also was unable to suppress TAZ activation of the TEAD promoter
(Figure 40). Yet, the mutant of NORE1A (ΔSARAH) that fails to bind MST, but still
binds GSK-3β, was still able to suppress TAZ mediated TEAD activation (Figure 40).
These observations correlate with my protein stability observations and show that
NORE1A mediated TAZ suppression indeed affects transcription of TEAD.

NORE1A coordinates with β-TrCP to control TAZ protein levels
I recently reported that NORE1A can form a direct, Ras regulated complex with
the E3 ubiquitin ligase, β-TrCP [212]. TAZ is known to be ubiquitinated by β-TrCP, and
it is entirely plausible that NORE1A may also be regulating TAZ by coordinating GSK-3β
with β -TrCP. To test this hypothesis, HEK-293 cells were transfected with expression
constructs expressing TAZ along with an empty vector, NORE1A, and β - TrCP. TAZ
protein levels were suppressed in the presence of NORE1A and β-TrCP, and the effect
was amplified when both NORE1A and β -TrCP were co-expressed with TAZ (Figure
41). However, when a dominant negative β -TrCP (ΔFBOX) was transfected into this
experimental system, it disrupted the ability of NORE1A to effectively down-regulate TAZ
(Figure 41), showing that NORE1A is also using β-TrCP to regulate TAZ.

NORE1A scaffolds β-TrCP and GSK-3β to form a protein regulatory complex
I have shown that NORE1A can complex with key elements of an ubiquitin ligase
mechanism that control phosphorylation and subsequent ubiquitination of substrates.
NORE1A has no apparent enzymatic activity and it is hypothesized to function as an
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NORE1A Suppresses TAZ Mediated TEAD Promoter Activity - To

investigate whether NORE1A mediated TAZ protein suppression (Figure 39) also
resulted in a suppression of TAZ mediated TEAD transcriptional co-activation, HEK293
cells were transfected with a TEAD luciferase reporter construct along with an
expression construct expressing TAZ. I then paired this system with either wild-type
NORE1A, the 92-94A mutant, or the truncation mutant lacking the SARAH domain.
Echoing the results from the protein stability experiment, wild type NORE1A (p=0.001)
and the mutant that fails to bind MST (ΔSARAH) (p=0.001) still both strongly suppressed
TAZ mediated transcriptional activity. The mutant of NORE1A that failed to bind GSK-3β
(92-94A) also failed to suppress TAZ (p=0.25) mediated transcriptional activity further
supporting my hypothesis that NORE1A is regulating TAZ independently of Hippo
signaling (MST) via GSK-3β.
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Figure 41. NORE1A Cooperates with β-TrCP to Regulate TAZ Protein Levels Phosphorylation of TAZ results in its recognition and subsequent ubiquitination by the E3
ubiquitin ligase, β-TrCP. I previously published that NORE1A can bind and regulate βTrCP, and I sought to see if NORE1A was also regulating TAZ via β -TrCP. HEK293
cells were transfected with expression constructs expressing TAZ along with NORE1A,
NORE1A paired with β-TrCP, and NORE1A paired with a catalytically inactivate β-TrCP
(ΔFBOX).

NORE1A suppression of TAZ was enhanced in the presence of β -TrCP.

Intriguingly, the effect was impaired when a dominant negative β-TrCP (ΔFBOX) was coexpressed with NORE1A.

Taken together, this supports that NORE1A is also

functioning through β-TrCP to regulate TAZ.
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effective scaffolding element.

Perhaps NORE1A regulates different cellular protein

substrates by scaffolding GSK-3β to β-TrCP and enhancing its mechanistic productivity.
To investigate this, HEK-293T cells were transfected with a HA-GSK-3β along with GFPVector or GFP-β-TrCP with and without Flag-NORE1A. Cells were lysed 24 hours posttransfection and the cell lysates were immunoprecipitated by the GFP-tag and analyzed
by Western blot. I found GSK-3β in a barely detectable complex with β-TrCP, however,
the addition of NORE1A strongly stabilized the complex (Figure 42). Thus, this data
suggests that NORE1A indeed works as a scaffolding protein stabilizing the GSK-3β and
β-TrCP into a protein complex. This observation helps explain how NORE1A functions
in the regulation of TAZ as well as helps support my hypothesis from Chapter IV where
NORE1A scaffolds GSK-3β to β-TrCP to Regulate β-catenin.

NORE1A cooperates with GSK-3β to induce cellular senescence
In primary mammalian cells, expression of oncogenes, such as activated Ras,
induces premature senescence rather than transformation [248].

Ras (Oncogene)

induced senescence can be bypassed by a number of different genetic events including
inactivation of the p53/p21/p19ARF pathway, inactivation of the Rb family of proteins,
and aberrations in p53, PML, SIR2, KLF4, and YAP/TAZ [248, 249]. Recent research
has now identified GSK-3β as a key player in the activation of cellular senescence [248,
250, 251]. These reports demonstrate that loss GSK-3β expression is a key factor that
determines whether a cell transforms or becomes senescent in the presence of
constitutively active Ras [248]. Exactly how GSK-3β functions in senescence is not
exactly clear and likely occurs on multiple levels including regulation of β-catenin, p53,
and potentially partial suppression of TEAD genes [248, 249, 252]. NORE1A is a
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Figure 42. NORE1A Scaffolds GSK-3β to β-TrCP - NORE1A may be functioning as a
scaffolding molecule stabilizing a protein degradation complex comprised of a priming
kinase and associated ubiquitin ligase. Reports have shown that TAZ protein levels are
regulated by GSK-3β and β -TrCP.

Perhaps NORE1A functions as a scaffolding

molecule and stabilizes these proteins in a complex. To test this, HEK-293T cells were
transfected with expression constructs for GSK-3β, β -TrCP, and NORE1A. 24 hours
post-transfection, cells were lysed and immunoprecipitated. GSK-3β and β -TrCP were
detected weakly in a complex. However, in the presence of NORE1A, the association
between GSK-3β and β-TrCP was greatly enhanced.
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powerful senescence effector that functions through both p53 and possibly other
pathways including Rb and p16 [14]. Now that I have shown that NORE1A binds and
scaffolds GSK-3β, and considering that both NORE1A and GSK-3β are implicated in
activating Ras (oncogene) induced senescence (OIS), I sought to determine whether
NORE1A functions through GSK-3β to shift cells into a senescent phenotype.

To

achieve this, I took A549 cells and transfected them with either an empty vector or an
expression construct expressing a GFP-tagged NORE1A. 6-hours post-transfection the
cells were then treated with LiCl2 or water, the carrier solution, at a final concentration
of10mM for 72-hours. The cells were then processed using a β-gal senescence kit. The
number of positive blue cells were counted and quantified. Results show that NORE1A
strongly induced a senescent phenotype in the A549 cells and this effect was
suppressed by the LiCl2 suggesting that NORE1A is using GSK-3β in part as a
senescence effector (Figure 43, 44).

NORE1A Induced Senescence is Suppressed By Overexpression of TAZ
While GSK-3β is known to be able to activate senescence via several cellular
targets including p53 and β-catenin[250, 251], recent research has now identified that
loss of TEAD transcriptional activity can also be a factor to induce cellular senescence
[249]. Accordingly, the potential exists that NORE1A’s regulation of TAZ via GSK-3β
functions as another arm of NORE1A senescence. Since I have shown that NORE1A
indeed induces senescence by GSK-3β, I were then curious whether this was due to its
regulation of TAZ or if NORE1A and GSK-3β were cooperating to induce senescence via
another target.
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Figure 43. Lithium Chloride Blocks the Ability of NORE1A to Induce Senescence NORE1A is a powerful inducer of senescence.

While p53 is one of the better-

characterized pathways in which NORE1A functions in senescence, I have data that
now suggests that NORE1A can also induce senescence through alterations in the
Hippo pathway endpoint, TAZ. Loss of TEAD promoter activity has been reported to
shift cells into senescence [249]. So, I sought to determine whether suppression of GSK3β impairs the ability of NORE1A to induce cellular senescence.

A549 cells were

transfected with expression constructs expressing an empty vector or NORE1A. 6-hours
post-transfection, the cells were treated with LiCl2 at a final concentration of 10mM for
72 hours. The cells were then processed for β-gal activity using a senescence detection
kit. The cells were then counted and the results quantified. As expected, NORE1A
strongly shifted cells into senescence (p=0.05). This effect was impaired in the presence
of LiCl2, supporting the hypothesis that NORE1A is working with GSK-3β to activate
senescence.
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Figure 44.

Representative Pictures from the NORE1A Senescence Assay -

Representative photographs taken of A549 cells in the senescence assay described in
Figure 10. Positive cells are easily seen with blue color, most prevalent in the A549 cells
transfected with NORE1A and not treated with LiCl2.
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To test this hypothesis, I surmised that excessive over-expression of TAZ would
over-come the ability of NORE1A to regulate TAZ and induce senescence, thus
reversing or suppressing the ability of NORE1A to induce senescence. A549 cells were
transfected with an empty, and expression construct for NORE1A, and then an
expression construct for NORE1A along with an expression construct for TAZ
transfected in a 5 times the amount used in previous experiments. Here I found that
NORE1A on its own increased the level of cellular senescence from roughly 12%
background level to roughly 42% (Figure 45).

However, when levels of TAZ were

elevated to where NORE1A could no longer successfully regulated them, the ability of
NORE1A to induce senescence was suppressed and only about 20% of the cells were
found to be β-gal positive (Figure 45). Thus, this experiment defines a novel NORE1A
senescence arm and NORE1A fulfills its role as a senescence effector by the
downregulation of TAZ, suppressing its ability to co-activate TEAD promoter genes.

5.3 - Discussion

The Hippo signaling pathway performs key roles in both organ size and
tumorigenesis; however, components of the Hippo pathway are deregulated in various
human cancers. In canonical Hippo signaling, the core mechanism employs a kinase
cascade consisting of the MST1/2 and LATS1/2 kinases to phosphorylate the major
functional output components YAP and TAZ, marking them for degradation [204, 253].
YAP and TAZ are transcriptional co-activators that exert powerful survival signals
and also have oncogenic potential when improperly regulated. They require precise and
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Figure 45.

Identification of a Novel NORE1A Senescence Arm – NORE1A

cooperates with GSK-3β to drive senescence by suppressing TAZ mediated coactivation of TEAD. A549 cells were transfected with expression constructs expressing
an empty vector, NORE1A, and NORE1A along with excessive levels of TAZ. NORE1A
again powerfully induces senescence (p=0.05). However, this induction is over-powered
when levels of TAZ rise above the ability of NORE1A to properly regulate it. Thus,
NORE1A is able to induce senescence by the downregulation of TEAD genes coactivated by TAZ.
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specific regulation to maintain cellular homeostasis.

YAP and TAZ each share

approximately 50% sequence homology, yet they contain differences including lack of an
N-terminal proline-rich domain and a SH3 binding motif [204]. This would suggest YAP
and TAZ potentially have both conserved and non-conserved modes of regulation [204].
YAP/TAZ are rarely found mutated in different cancers, yet improper regulation of these
proteins is commonly observed in human tumors [254, 255]. Conversely, suppression of
YAP and TAZ protein levels results in inhibition of cellular proliferation and a shift to
apoptosis and senescence [256]. Taken together, this suggests that its not mutations in
YAP and TAZ specifically, but dysfunction in their regulatory mechanisms that can drive
oncogenesis.
Although YAP and TAZ are co-regulated by Hippo signaling, TAZ differs from
YAP in possessing a unique, Hippo independent phospho-degron [18]. This phosphodegron is recognized by the GSK-3β kinase and phosphorylation of TAZ by GSK-3β
promotes its degradation via the β-TrCP degradation complex. Thus, TAZ and YAP can
be both co- and differentially regulated.
One of the inputs that can regulate the Hippo pathway is Ras [232, 257].
Although Ras is a potent oncoprotein and is implicated in the development of the
majority of human tumors [258, 259], activated Ras is paradoxically capable of
stimulating apoptosis and senescence [7, 14]. The Hippo pathway is one of the best
characterized of these Ras death effector pathways.

Ras is connected to Hippo

pathway by its effector RASSF1A. RASSF1A is a member of the RASSF family of
proteins and directly binds MST kinases [260]. The interaction of Ras with RASSF1A
promotes the activation of the MST kinases and therefore Hippo pathway activation,
leading to down-regulation of YAP.

Many tumors exhibit loss of RASSF1A expression

[126, 261], thus uncoupling Ras from Hippo and facilitating transformation.
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NORE1A, like RASSF1A, is a RASSF family member that serves as a direct, proapoptotic Ras effector [10, 11]. NORE1A suppresses tumor cell growth, is frequently
inactivated in human tumors, and genetic inactivation of NORE1A is implicated in a
hereditary cancer syndrome [15, 126, 187]. Therefore, NORE1A is likely to serve as an
important human tumor suppressor and its loss results in a marked cellular oncogenic
shift. Like RASSF1A, NORE1A also binds the MST kinases directly, and thus has the
potential to connect Ras to the Hippo pathway [10].

However, deletion mutants of

NORE1A that cannot interact with MST kinases retain the ability to inhibit cell growth
and suppress the tumorigenic phenotype [129].

Moreover, a thorough biochemical

analysis did not support an obvious role for NORE1A in MST kinase activation [135].
Thus, unknown tumor suppressor pathways independent of the canonical Hippo
signaling pathway must be modulated by NORE1A.
We recently showed that NORE1 forms a direct, endogenous complex with β TrCP [212]. β -TrCP is the E3 substrate recognition component for the SCF-β-TrCP
ubiquitin ligase complex, and is a key element in regulation of both Wnt and Hippo.
During my experiments examining the role of NORE1A in Hippo signaling, I noticed that
NORE1A appeared much more active towards TAZ than YAP. Bearing in mind it has
been shown that NORE1A does not seem to activate MST kinases, even though it binds
them [135], I wondered if NORE1A might be activating a TAZ specific/β-TrCP noncanonical degradative pathway.
My experiments have shown that NORE1A does indeed preferentially suppress
cellular TAZ protein levels via β -TrCP. However, I also found that NORE1A not only
interacts with β -TrCP, but also forms an endogenous complex with the kinase
responsible for TAZ phosphorylation: Glycogen synthase kinase 3 Beta (GSK-3β).
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GSK-3β is a serine/threonine kinase that is an important component of diverse
signaling pathways involved in the regulation of cell survival, protein synthesis, glycogen
metabolism, cell mobility, and proliferation [220]. It appears to function to suppress
tumorigenesis, yet the roles in which GSK-3β operates as a tumor suppressor are not
fully characterized [221].

One of the better-studied roles of GSK-3β in tumor

suppression is centered on its control of β -catenin, the terminal executor of the Wnt
signaling pathway. Phosphorylation of β-catenin by GSK-3β targets it for ubiquitination
by the substrate recognition protein β -TrCP resulting in its subsequent proteasomal
degradation.
Unlike many other protein kinases in the cell, GSK-3β has constitutively active
kinase activity [262]. Thus, control of GSK-3β function may rely on targeting proteins
that control it’s coupling to the appropriate substrate. NORE1A may serve as one of
these targeting proteins, for when I used a specific GSK-3β inhibitor; I blocked the ability
of NORE1A to promote TAZ degradation. Thus I reveal a new function for NORE1A as
a scaffolding molecule for GSK-3β. This links NORE1A to the potential control of a
broad range of targets some of which include β-catenin, Snail, Smad1, Smad3, BCL-3,
p21, HIF-1α, and Cyclin D1 [263]. However, although I found that the interaction of
NORE1A with β -TrCP was Ras dependent [212], its interaction with GSK-3β was not.
Therefore, NORE1A may have Ras dependent and Ras independent effects on GSK-3β
activity.
One of the most interesting aspects of this study is the revelation that NORE1A
differentially regulates Hippo pathway endpoints.

Much of the research on RASSF

family proteins attributed their tumor suppressive capabilities to their binding of the MST
kinases, and subsequent activation of canonical Hippo signaling as a conserved
function. However, closer examination of the relationship between RASSF proteins and
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Hippo has revealed that their relationship is much more complicated [129, 133]. While it
is well demonstrated that RASSF1A can regulate YAP stability by enhancing MST/LATS
phosphorylation on S127, I have never observed NORE1A to do the same, despite the
fact that I, and others, have shown that NORE1A complexes with MST. Thus, NORE1A
must be performing other tasks with MST; however these tasks are not involved in the
regulation of Hippo signaling and at this point remain largely uncharacterized.
NORE1A still remains connected into the Hippo signaling pathway, but unlike its
close family relative, RASSF1A, NORE1A functions non-canonically and specifically
regulates the Hippo pathway endpoint, TAZ. Initially, I was unsure what the implications
of the specific regulation of one of the two Hippo pathway endpoints were on the cell
until I found a report showing that varying degrees of alterations in TEAD transcriptional
output alter whether the pathway is apoptotic or senescent [249]. Explained further, the
full suppression of YAP and TAZ mediated TEAD activation by canonical Hippo signaling
is indeed apoptotic, yet partial suppression of TEAD by specific regulation of YAP or
TAZ by non-canonical mechanisms induces a senescent phenotype preferentially over
the activation of apoptosis. This provides some of the first explanations why RASSF1A
appears to be an apoptotic effector while NORE1A appears to be a senescence effector.
Thus, I identify a novel role for NORE1A in scaffolding the protein kinase GSK-3β
to ubiquitin ligase β-TrCP. NORE1A is key in the stabilization of this complex and loss
of NORE1A impairs the ability of GSK-3β and β-TrCP to properly regulate substrates
such as TAZ. Furthermore, I now know that NORE1A can complex with several other
kinases involved in β-TrCP phosphodegron process including HIPK2 [14], Aurora
Kinase, and PLK-1 (unpublished observations). Thus, this highlights a new potential role
for NORE1A in protein regulation by functioning mechanistically as a scaffolding various
protein kinases to β-TrCP
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CHAPTER VI

CONCLUSION

This work identifies a completely new and unanticipated signaling pathway for
the Ras oncogene. It reveals that NORE1A forms a direct, physiological, Ras regulated
complex with the ubiquitin ligase substrate recognition protein β-TrCP. This allows Ras
to use NORE1A as an effector to regulate the stability of multiple proteins playing key
roles in growth, transformation, and death. Mechanistically, it shows NORE1A acts as a
scaffolding protein facilitating complex formation between GSK-3β and β-TrCP to
enhance proteasomal regulation of β-catenin and TAZ, which are the active end points
of the Wnt and Hippo pathways respectively (Figure 46).
These results provide a mechanistic explanation for some of the contradictory
reports previously published in the literature describing the relationship between Ras
and Wnt. In the presence of NORE1A Ras is a negative regulator of β-catenin, but in its
absence is a positive regulator. Moreover, these results also explain discrepancies in
the reported role of NORE1A in the regulation of the Hippo pathway. They show that
NORE1A does not activate the canonical Hippo pathway, but exhibits a potent and
specific non-canonical regulation of the TAZ half the YAP/TAZ transcriptional coactivator endpoints of Hippo signaling. This allows us to explain why NORE1A is far
more pro-senescent than pro-apoptotic.
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Figure 46. Diagram of the Novel Ras/NORE1A/GSK-3β/β-TrCP Signaling Pathway
– This schematic shows the previously accepted model for NORE1A mediated tumor
suppression (A) along with my Novel Ras/NORE1A signaling pathway allowing for the
coordinate control of the Wnt (β-catenin) and Hippo (TAZ) signaling pathways (B). My
results show that NORE1A scaffolds GSK-3β to β-TrCP qualitatively and quantitatively
enhancing their phosphorylation and ubiquitination of oncogenic substrates. Moreover, I
identify a novel NORE1A senescence arm where NORE1A splits the Hippo, specifically
regulating TAZ and not YAP, resulting in the partial suppression of TEAD transcriptional
activity and the activation of cellular senescence.
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Experiments showing that NORE1A has no effect on the β-TrCP target IκB
confirmed that the pathway is specific to a sub-set of the broad range of β-TrCP target
proteins.

This may help explain why β-TrCP has been reported to exhibit both

oncogenic and tumor suppressive functions in different systems as levels of NORE1A
present may dictate its balance of forces.
Future studies should be centered on finding other kinases that cooperate with βTrCP in protein regulation and investigating whether NORE1A also scaffolds them into a
single kinase/ubiquitin ligase complex.

Key kinases worth investigating are PLK-1

(involved in Claspin regulation), HIPK2 (involved in regulation of numerous proteins),
and RSK1 (involved in DEPTOR regulation).

Additionally, other β-TrCP substrates

should be examined to see if NORE1A is involved in their regulation as well. One that
immediately comes to mind is the MDM2 ubiquitin ligase. This ubiquitin ligase controls
p53 stability and since NORE1A and p53 cooperate to induce senescence, a Ras
regulated mechanism where NORE1A cooperates to negatively regulate MDM2 is an
intriguing possibility and warrants examination.

Such an interaction might allow co-

ordinate suppression of TAZ and activation of p53 to achieve senescence.
Finally, this project may also have ramifications for personalized medicine
focused on Ras tumors, as Ras tumors lacking NORE1A expression may be quite
different in the utilization of the Wnt and Hippo pathways compared to those retaining
the expression of NORE1A. Therefore, patients receiving treatments for a Rasopathy
should have the NORE1A status of the tumor determined to see if they require
coordinate therapies targeting Wnt and Hippo as well the oncogenic form of Ras.
Coordinate therapies may enhance the effectiveness of targeting mutated Ras and may
finally give cancer patients a better chance for surviving cancer.
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